name,smiles,label100,phase,moa,drug_category,label
fludroxycortide,CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer,58
verapamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC,0,Launched,calcium channel blocker,noncancer,45
methacholine,CC(C[N+](C)(C)C)OC(C)=O,0,Launched,acetylcholine receptor agonist,noncancer,27
macitentan,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,0,Launched,endothelin receptor antagonist,Unknown,55
ABT-639,Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F,0,Phase 2,calcium channel blocker,noncancer,45
oxiconazole,Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
ibuprofen-piconol,CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1,0,Launched,cyclooxygenase inhibitor,noncancer,49
JNJ-7706621,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,1,Preclinical,CDK inhibitor,targeted cancer,5
SKF-86002,Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1,0,Preclinical,p38 MAPK inhibitor,noncancer,75
NNC-63-0532,COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O,0,Preclinical,opioid receptor agonist,noncancer,73
N-alpha-Methylhistamine-dihydrochloride,CNCCc1cnc[nH]1,0,Phase 3,histamine receptor agonist,noncancer,62
trametinib,CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O,1,Launched,MEK inhibitor,targeted cancer,18
docetaxel,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C,1,Launched,tubulin polymerization inhibitor,chemo,91
lorcaserin,C[C@H]1CNCCc2ccc(Cl)cc12,0,Launched,serotonin receptor agonist,noncancer,85
loperamide,CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1,0,Launched,opioid receptor agonist,noncancer,73
carumonam,NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
oleuropein,COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCc1ccc(O)c(O)c1,0,Phase 2,estrogen receptor agonist,targeted cancer,56
bromperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,0,Launched,dopamine receptor antagonist,noncancer,53
moxifloxacin,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
roxarsone,Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O,0,Launched,antiprotozoal agent,Unknown,38
afloqualone,Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O,0,Launched,acetylcholine receptor antagonist,noncancer,28
4-HQN,Oc1ncnc2ccccc12,0,Preclinical,PARP inhibitor,targeted cancer,20
dienogest,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,Launched,progesterone receptor agonist,noncancer,79
famciclovir,CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O,1,Launched,DNA polymerase inhibitor,noncancer,8
SB-269970,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,0,Preclinical,serotonin receptor antagonist,noncancer,86
CCT128930,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,1,Preclinical,AKT inhibitor,targeted cancer,0
doxapram,CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1,0,Launched,potassium channel blocker,noncancer,78
JNJ-16259685,CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1,1,Preclinical,glutamate receptor antagonist,noncancer,60
R306465,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,1,Phase 1,HDAC inhibitor,Unknown,14
2'-MeCCPA,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12,1,Preclinical,adenosine receptor agonist,noncancer,30
cefminox,CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
cisapride,COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC,0,Withdrawn,serotonin receptor agonist,noncancer,85
butoconazole,Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
pantoprazole,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,0,Launched,ATPase inhibitor,Unknown,2
nornicotine,C1CNC(C1)c1cccnc1,0,Preclinical,acetylcholine receptor agonist,noncancer,27
perzinfotel,OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O,0,Phase 2,glutamate receptor antagonist,noncancer,60
SB-200646,Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12,1,Preclinical,serotonin receptor antagonist,noncancer,86
CGP-7930,CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,0,Preclinical,GABA receptor modulator,noncancer,12
streptozotocin,CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,Launched,DNA alkylating agent,chemo,6
tocainide,CC(N)C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer,87
afatinib,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,Launched,EGFR inhibitor,targeted cancer,10
vesnarinone,COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1,0,Launched,phosphodiesterase inhibitor,noncancer,76
7-chlorokynurenic-acid,OC(=O)c1cc(O)c2ccc(Cl)cc2n1,0,Preclinical,glutamate receptor antagonist,noncancer,60
golvatinib,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,1,Phase 2,VEGFR inhibitor,targeted cancer,26
trandolapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
sarafloxacin,OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer,41
iopamidol,C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,0,Launched,radiopaque medium,noncancer,82
niraparib,NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1,1,Launched,PARP inhibitor,targeted cancer,20
AZ-628,Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1,1,Preclinical,RAF inhibitor,targeted cancer,23
doxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,1,Launched,topoisomerase inhibitor,Unknown,90
epirizole,COc1cc(C)nn1-c1nc(C)cc(OC)n1,0,Launched,cyclooxygenase inhibitor,noncancer,49
sulfabenzamide,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,1,Launched,bacterial antifolate,noncancer,42
L-745870,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,0,Preclinical,dopamine receptor antagonist,noncancer,53
alizapride,COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C,0,Launched,dopamine receptor antagonist,noncancer,53
nemorubicin,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,1,Phase 2,topoisomerase inhibitor,Unknown,90
AT7867,Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1,1,Preclinical,AKT inhibitor,targeted cancer,0
marbofloxacin,CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
ropivacaine,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer,87
SKA-31,Nc1nc2c(ccc3ccccc23)s1,0,Preclinical,potassium channel activator,noncancer,77
demecarium,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,1,Launched,acetylcholinesterase inhibitor,noncancer,29
vancomycin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
ciprofibrate,CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O,1,Launched,PPAR receptor agonist,noncancer,22
deferasirox,OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,1,Launched,chelating agent,noncancer,47
gavestinel,OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1,0,Phase 3,glutamate receptor antagonist,noncancer,60
adaprev,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,1,Phase 3,TGF beta receptor inhibitor,noncancer,25
cefpirome,CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
pirenperone,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,1,Preclinical,serotonin receptor antagonist,noncancer,86
SCH-23390,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,0,Preclinical,dopamine receptor antagonist,noncancer,53
acitretin,COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C,0,Launched,retinoid receptor agonist,noncancer,83
carmoxirole,OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1,0,Phase 2,dopamine receptor agonist,noncancer,52
reboxetine,CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1,0,Launched,adrenergic receptor antagonist,Unknown,33
gamma-aminobutyric-acid,NCCCC(O)=O,1,Preclinical,benzodiazepine receptor agonist,noncancer,44
ephedrine-(racemic),CNC(C)C(O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer,32
brinzolamide,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer,46
vardenafil,CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1,0,Launched,phosphodiesterase inhibitor,noncancer,76
"ICI-215,001",O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,0,Preclinical,adrenergic receptor agonist,noncancer,32
alfuzosin,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1,0,Launched,adrenergic receptor antagonist,noncancer,33
moprolol,COc1ccccc1OCC(O)CNC(C)C,0,Launched,adrenergic receptor antagonist,noncancer,33
thioperamide,S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1,0,Preclinical,histamine receptor antagonist,noncancer,63
dydrogesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,0,Launched,progesterone receptor agonist,noncancer,79
perindopril,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
sumanirole,CN[C@@H]1Cc2cccc3nc(O)n(C1)c23,0,Phase 3,dopamine receptor agonist,noncancer,52
CUDC-907,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,1,Phase 2,PI3K inhibitor,Unknown,21
acetylsalicylsalicylic-acid,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,1,Preclinical,cyclooxygenase inhibitor,noncancer,49
trimethobenzamide,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,0,Launched,histamine receptor antagonist,noncancer,63
nicotine,CN1CCCC1c1cccnc1,1,Launched,acetylcholine receptor agonist,noncancer,27
nizatidine,CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O,1,Launched,histamine receptor antagonist,noncancer,63
oxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
KD025,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,1,Phase 2,rho associated kinase inhibitor,targeted cancer,84
cloxyquin,Oc1ccc(Cl)c2cccnc12,0,Preclinical,potassium channel activator,noncancer,77
NMS-873,Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O,1,Preclinical,ATPase inhibitor,targeted cancer,2
homoharringtonine,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,1,Launched,protein synthesis inhibitor,Unknown,81
sulindac,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
tioconazole,Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl,0,Launched,sterol demethylase inhibitor,Unknown,88
genz-644282,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,1,Phase 1,topoisomerase inhibitor,Unknown,90
dexlansoprazole,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,0,Launched,ATPase inhibitor,noncancer,2
budipine,CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1,0,Launched,glutamate receptor antagonist,noncancer,60
L-733060,FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F,0,Preclinical,tachykinin antagonist,noncancer,89
quinagolide,CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC,0,Launched,dopamine receptor agonist,noncancer,52
ganciclovir,Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1,0,Launched,DNA polymerase inhibitor,noncancer,8
INCB-3284,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,0,Phase 2,CC chemokine receptor antagonist,noncancer,4
moxisylyte,CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C,0,Withdrawn,adrenergic receptor antagonist,noncancer,33
rivastigmine,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer,29
sitaxentan,Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl,0,Withdrawn,endothelin receptor antagonist,noncancer,55
butalbital,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,0,Launched,GABA receptor antagonist,noncancer,11
pergolide,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,0,Withdrawn,dopamine receptor agonist,noncancer,52
dehydrocorydaline,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC,0,Phase 3,acetylcholinesterase inhibitor,noncancer,29
oxiracetam,NC(=O)CN1C[C@H](O)CC1=O,1,Launched,acetylcholine receptor agonist,noncancer,27
PP242,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12,1,Preclinical,mTOR inhibitor,targeted cancer,67
bromocriptine,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C,0,Launched,dopamine receptor agonist,noncancer,52
naltrindole,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O,0,Preclinical,opioid receptor antagonist,noncancer,74
roxatidine-acetate,CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1,0,Launched,histamine receptor antagonist,noncancer,63
VT-464,CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1,0,Phase 2,cytochrome P450 inhibitor,targeted cancer,50
tiprenolol,CSc1ccccc1OCC(O)CNC(C)C,0,Phase 2,adrenergic receptor antagonist,noncancer,33
istradefylline,CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O,1,Launched,adenosine receptor antagonist,noncancer,31
ibutilide,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,1,Launched,potassium channel blocker,noncancer,78
tapentadol,CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1,0,Launched,opioid receptor agonist,Unknown,73
molindone,CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,0,Launched,dopamine receptor antagonist,noncancer,53
methyldopa,C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O,1,Launched,adrenergic receptor agonist,noncancer,32
ketanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,0,Launched,serotonin receptor antagonist,noncancer,86
PF-04136309,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,1,Phase 2,CC chemokine receptor antagonist,targeted cancer,4
lorlatinib,C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,1,Phase 2,ALK tyrosine kinase receptor inhibitor,Unknown,1
prednisolone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer,58
mephentermine,CNC(C)(C)Cc1ccccc1,0,Launched,adrenergic receptor agonist,noncancer,32
sangivamycin,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,1,Phase 1,DNA inhibitor,Unknown,7
quetiapine,OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
CL-218872,Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F,1,Phase 1,benzodiazepine receptor agonist,noncancer,44
WZ-4002,COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1,1,Preclinical,EGFR inhibitor,targeted cancer,10
lidamidine,CNC(=N)NC(=O)Nc1c(C)cccc1C,1,Launched,adrenergic receptor agonist,noncancer,32
adiphenine,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
triciribine,Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,1,Phase 1/Phase 2,AKT inhibitor,targeted cancer,0
elafibranor,CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1,0,Phase 3,PPAR receptor agonist,targeted cancer,22
silibinin,COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O,0,Launched,cytochrome P450 inhibitor,noncancer,50
bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,0,Launched,PPAR receptor agonist,noncancer,22
"1s,2r-phenylpropanolamine",C[C@@H](N)[C@@H](O)c1ccccc1,0,Withdrawn,adrenergic receptor agonist,noncancer,32
lincomycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
CS-110266,C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1,1,Preclinical,dopamine receptor agonist,noncancer,52
alpelisib,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,1,Phase 3,PI3K inhibitor,targeted cancer,21
pramiracetam,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,0,Launched,acetylcholine receptor agonist,noncancer,27
crisaborole,OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12,0,Phase 3,phosphodiesterase inhibitor,noncancer,76
bekanamycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,1,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
ambrisentan,COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1,0,Launched,endothelin receptor antagonist,noncancer,55
nabumetone,COc1ccc2cc(CCC(C)=O)ccc2c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
clorprenaline,CC(C)NCC(O)c1ccccc1Cl,0,Launched,adrenergic receptor agonist,noncancer,32
istaroxime,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,0,Phase 2,ATPase inhibitor,noncancer,2
meprylcaine,CCCNC(C)(C)COC(=O)c1ccccc1,0,Preclinical,local anesthetic,noncancer,66
almotriptan,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,0,Launched,serotonin receptor agonist,noncancer,85
mocetinostat,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1,1,Phase 2,HDAC inhibitor,Unknown,14
TAK-063,COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1,0,Phase 2,phosphodiesterase inhibitor,noncancer,76
icariin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,0,Phase 3,phosphodiesterase inhibitor,targeted cancer,76
finafloxacin,OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer,41
7-methoxytacrine,COc1ccc2nc3CCCCc3c(N)c2c1,0,Phase 2,acetylcholinesterase inhibitor,noncancer,29
N20C,NC(=O)CNCCC(c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor antagonist,targeted cancer,60
procainamide,CCN(CC)CCNC(=O)c1ccc(N)cc1,0,Launched,sodium channel blocker,noncancer,87
metrizoic-acid,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I,0,Launched,radiopaque medium,Unknown,82
etilevodopa,CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,0,Phase 3,dopamine receptor agonist,noncancer,52
talnetant,CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,0,Phase 2,tachykinin antagonist,noncancer,89
naloxone-benzoylhydrazone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1,0,Preclinical,opioid receptor antagonist,noncancer,74
bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F,1,Launched,androgen receptor antagonist,targeted cancer,34
PCI-24781,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,1,Phase 1/Phase 2,HDAC inhibitor,targeted cancer,14
canertinib,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,1,Phase 3,EGFR inhibitor,targeted cancer,10
maraviroc,CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,0,Launched,CC chemokine receptor antagonist,noncancer,4
T-0156,COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,0,Preclinical,phosphodiesterase inhibitor,noncancer,76
semagacestat,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O,0,Phase 3,gamma secretase inhibitor,noncancer,57
fenoldopam,Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12,0,Launched,dopamine receptor agonist,noncancer,52
asymmetrical-dimethylarginine,CN(C)C(=N)NCCC[C@H](N)C(O)=O,1,Phase 1,nitric oxide synthase inhibitor,noncancer,72
BRL-15572,OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1,0,Preclinical,serotonin receptor antagonist,noncancer,86
puerarin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,0,Phase 2,serotonin receptor antagonist,noncancer,86
methyllycaconitine,CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14,0,Preclinical,acetylcholine receptor antagonist,noncancer,28
norepinephrine,NC[C@H](O)c1ccc(O)c(O)c1,1,Launched,adrenergic receptor agonist,noncancer,32
cefdinir,Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,1,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C,1,Phase 2,HSP inhibitor,Unknown,16
bicuculline-(+),CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21,0,Preclinical,GABA receptor antagonist,noncancer,11
atrasentan,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1,0,Phase 3,endothelin receptor antagonist,targeted cancer,55
BF2.649,Clc1ccc(CCCOCCCN2CCCCC2)cc1,1,Phase 3,histamine receptor antagonist,noncancer,63
estramustine,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,1,Launched,DNA alkylating agent,chemo,6
ebastine,CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,1,Launched,histamine receptor antagonist,noncancer,63
pumosetrag,Oc1c(cnc2ccsc12)C(=O)N[C@H]1CN2CCC1CC2,0,Phase 2,serotonin receptor agonist,noncancer,85
SB-505124,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,1,Preclinical,ALK tyrosine kinase receptor inhibitor,noncancer,1
alvimopan,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1,0,Launched,opioid receptor antagonist,noncancer,74
ceftibuten,Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
CF102,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12,0,Phase 2,adenosine receptor agonist,targeted cancer,30
GR-113808,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12,0,Preclinical,serotonin receptor antagonist,noncancer,86
tozadenant,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,0,Phase 3,adenosine receptor antagonist,noncancer,31
BQ-123,CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C,0,Phase 2,endothelin receptor antagonist,noncancer,55
mabuprofen,CC(C)Cc1ccc(cc1)C(C)C(=O)NCCO,0,Launched,cyclooxygenase inhibitor,noncancer,49
amprenavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,0,Launched,HIV protease inhibitor,noncancer,15
secoisolariciresinol-diglucoside,COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O,0,Phase 2,antioxidant,noncancer,37
boceprevir,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,0,Launched,HCV inhibitor,noncancer,13
GDC-0941,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,1,Phase 2,PI3K inhibitor,targeted cancer,21
5-hydroxymethyl-tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C,1,Phase 1,acetylcholine receptor antagonist,noncancer,28
amibegron,CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1,0,Phase 3,adrenergic receptor agonist,noncancer,32
ascorbic-acid,OC[C@H](O)[C@H]1OC(=O)C(=O)C1O,0,Launched,antioxidant,noncancer,37
AZD5363,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,1,Phase 2,AKT inhibitor,targeted cancer,0
YM-58483,Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F,0,Preclinical,calcium channel blocker,noncancer,45
clindamycin-phosphate,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,1,Launched,protein synthesis inhibitor,noncancer,81
sotalol,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,0,Launched,adrenergic receptor antagonist,noncancer,33
alprenolol,CC(C)NCC(O)COc1ccccc1CC=C,0,Launched,adrenergic receptor antagonist,noncancer,33
metaxalone,Cc1cc(C)cc(OCC2CNC(=O)O2)c1,0,Launched,muscle relaxant,noncancer,71
flumequine,CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,topoisomerase inhibitor,noncancer,90
nebivolol,O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,0,Launched,adrenergic receptor antagonist,noncancer,33
perifosine,CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1,0,Phase 3,AKT inhibitor,targeted cancer,0
metrizamide,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I,0,Launched,radiopaque medium,noncancer,82
pronethalol,CC(C)NCC(O)c1ccc2ccccc2c1,0,Withdrawn,adrenergic receptor antagonist,noncancer,33
cimetidine,CN\C(NCCSCc1nc[nH]c1C)=N/C#N,1,Launched,histamine receptor antagonist,targeted cancer,63
chidamide,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,1,Launched,HDAC inhibitor,targeted cancer,14
BMS-299897,C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O,0,Phase 1,gamma secretase inhibitor,noncancer,57
itraconazole,CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O,1,Launched,cytochrome P450 inhibitor,noncancer,50
D-4476,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1,1,Preclinical,TGF beta receptor inhibitor,noncancer,25
2-methyl-5-hydroxytryptamine,Cc1[nH]c2ccc(O)cc2c1CCN,0,Preclinical,serotonin receptor agonist,noncancer,85
chlorprothixene,CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12,0,Launched,dopamine receptor antagonist,noncancer,53
semaxanib,Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1,1,Phase 3,VEGFR inhibitor,targeted cancer,26
remoxipride,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,1,Withdrawn,dopamine receptor antagonist,noncancer,53
r(-)-apomorphine,CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31,0,Launched,dopamine receptor agonist,noncancer,52
lansoprazole,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,0,Launched,ATPase inhibitor,noncancer,2
piroxicam,CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O,1,Launched,cyclooxygenase inhibitor,noncancer,49
NMS-E973,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,1,Preclinical,HSP inhibitor,targeted cancer,16
flutamide,CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,1,Launched,androgen receptor antagonist,targeted cancer,34
diazoxide,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,0,Launched,potassium channel activator,noncancer,77
metipranolol,CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C,0,Withdrawn,adrenergic receptor antagonist,noncancer,33
scopolamine-n-oxide,C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,0,Preclinical,acetylcholine receptor antagonist,noncancer,28
tubocurarine,COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4,0,Launched,acetylcholine receptor antagonist,Unknown,28
BMS-265246,CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F,1,Preclinical,CDK inhibitor,targeted cancer,5
alogliptin,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O,1,Launched,dipeptidyl peptidase inhibitor,noncancer,51
tacrine,Nc1c2CCCCc2nc2ccccc12,0,Launched,acetylcholinesterase inhibitor,noncancer,29
propiverine,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
dorzolamide,CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,1,Launched,carbonic anhydrase inhibitor,noncancer,46
picrotin,CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C,0,Phase 2,GABA receptor antagonist,noncancer,11
EGF816,CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12,0,Phase 2,EGFR inhibitor,targeted cancer,10
DNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
PI-828,Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1,1,Preclinical,PI3K inhibitor,noncancer,21
JNJ-26481585,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,1,Phase 2,HDAC inhibitor,Unknown,14
SD-169,NC(=O)c1ccc2[nH]ccc2c1,0,Preclinical,p38 MAPK inhibitor,noncancer,75
cinanserin,CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1,0,Preclinical,serotonin receptor antagonist,noncancer,86
penicillamine-(D),CC(C)(S)[C@@H](N)C(O)=O,1,Launched,chelating agent,noncancer,47
AZD1446,Clc1ccc(o1)C(=O)N1CC2CNCC2C1,0,Phase 2,acetylcholine receptor agonist,noncancer,27
clofedanol,CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl,0,Launched,histamine receptor antagonist,noncancer,63
sumatriptan,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,0,Launched,serotonin receptor agonist,noncancer,85
butamben,CCCCOC(=O)c1ccc(N)cc1,1,Withdrawn,sodium channel blocker,noncancer,87
dantrolene,[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1,0,Launched,calcium channel blocker,noncancer,45
torin-1,CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1,1,Preclinical,mTOR inhibitor,Unknown,67
indinavir,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12,0,Launched,HIV protease inhibitor,noncancer,15
methazolamide,CC(=O)N=c1sc(nn1C)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer,46
WZ811,C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1,0,Preclinical,CC chemokine receptor antagonist,targeted cancer,4
phentolamine,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1,0,Launched,adrenergic receptor antagonist,noncancer,33
avagacestat,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1,0,Phase 2,gamma secretase inhibitor,noncancer,57
uprosertib,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,1,Phase 2,AKT inhibitor,targeted cancer,0
loreclezole,Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl,0,Phase 2,benzodiazepine receptor agonist,noncancer,44
quinidine,COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,1,Launched,sodium channel blocker,noncancer,87
SB-939,CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO,1,Phase 2,HDAC inhibitor,targeted cancer,14
SNS-314,Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1,1,Phase 1,Aurora kinase inhibitor,targeted cancer,3
grazoprevir,COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C,0,Launched,HCV inhibitor,noncancer,13
Y-27632,C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1,1,Preclinical,rho associated kinase inhibitor,targeted cancer,84
imidafenacin,Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
iocetamic-acid,CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O,0,Launched,radiopaque medium,noncancer,82
torcitabine,Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,0,Phase 2,DNA polymerase inhibitor,noncancer,8
GW-7647,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O,0,Preclinical,PPAR receptor agonist,noncancer,22
acamprosate,CC(=O)NCCCS(O)(=O)=O,0,Launched,glutamate receptor antagonist,noncancer,60
SB-225002,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O,1,Preclinical,CC chemokine receptor antagonist,noncancer,4
timolol,CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1,0,Launched,adrenergic receptor antagonist,noncancer,33
amiloride,NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,0,Launched,sodium channel blocker,noncancer,87
S-14506,COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,0,Preclinical,serotonin receptor agonist,noncancer,85
foretinib,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,1,Phase 2,VEGFR inhibitor,targeted cancer,26
ramipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,Unknown,35
megestrol-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,0,Launched,progesterone receptor agonist,noncancer,79
lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1,0,Launched,HIV protease inhibitor,Unknown,15
CMPD-1,Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1,1,Preclinical,p38 MAPK inhibitor,noncancer,75
DPPE,CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,0,Phase 3,histamine receptor antagonist,Unknown,63
ATPA,CC(C)(C)c1onc(O)c1CC(N)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
ciclopirox,Cc1cc(C2CCCCC2)n(O)c(=O)c1,1,Launched,membrane integrity inhibitor,noncancer,68
foscarnet,OC(=O)P(O)(O)=O,1,Launched,DNA polymerase inhibitor,noncancer,8
N-benzylnaltrindole,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1,0,Preclinical,opioid receptor antagonist,noncancer,74
piperazinedione,O=C1CNC(=O)CN1,0,Phase 2,DNA synthesis inhibitor,noncancer,9
cobimetinib,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,1,Launched,MEK inhibitor,targeted cancer,18
PD-102807,CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12,0,Preclinical,acetylcholine receptor antagonist,noncancer,28
mesna,OS(=O)(=O)CCS,1,Launched,antioxidant,noncancer,37
methylergometrine,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",Unknown,54
difluprednate,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,1,Launched,glucocorticoid receptor agonist,noncancer,58
dexamethasone-sodium-phosphate,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O,0,Launched,glucocorticoid receptor agonist,noncancer,58
theophylline,Cn1c2nc[nH]c2c(=O)n(C)c1=O,1,Launched,adenosine receptor antagonist,noncancer,31
ifosfamide,ClCCNP1(=O)OCCCN1CCCl,1,Launched,DNA alkylating agent,chemo,6
LGX818,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,1,Phase 3,RAF inhibitor,targeted cancer,23
clemizole,Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1,0,Launched,HCV inhibitor,noncancer,13
3-carboxy-4-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
cefpiramide,Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1,1,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
ziprasidone,Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12,1,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
urethane,CCOC(N)=O,0,Preclinical,local anesthetic,noncancer,66
CX-5461,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,1,Phase 1,RNA polymerase inhibitor,targeted cancer,24
narasin,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,1,Launched,antiprotozoal agent,noncancer,38
SDZ-220-581,N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
arecaidine-propargyl-ester,CN1CCC=C(C1)C(=O)OCC#C,0,Preclinical,acetylcholine receptor agonist,Unknown,27
enrofloxacin,CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
taltobulin,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,1,Phase 1,tubulin polymerization inhibitor,chemo,91
cyamemazine,CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N,0,Launched,serotonin receptor antagonist,noncancer,86
arotinolol,CC(C)(C)NCC(O)CSc1nc(cs1)-c1ccc(s1)C(N)=O,0,Launched,adrenergic receptor antagonist,noncancer,33
nalfurafine,CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1,0,Launched,opioid receptor agonist,noncancer,73
7-hydroxy-DPAT,CCCN(CCC)C1CCc2ccc(O)cc2C1,0,Preclinical,dopamine receptor agonist,noncancer,52
azacyclonol,OC(C1CCNCC1)(c1ccccc1)c1ccccc1,0,Preclinical,histamine receptor antagonist,noncancer,63
etofibrate,CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,0,Launched,PPAR receptor agonist,noncancer,22
E7449,O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23,1,Phase 1/Phase 2,PARP inhibitor,targeted cancer,20
eszopiclone,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)c2nccnc12)c1ccc(Cl)cn1,0,Launched,benzodiazepine receptor agonist,noncancer,44
SR-59230A,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12,0,Preclinical,adrenergic receptor antagonist,noncancer,33
dexamethasone,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer,58
arctigenin,COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O,1,Preclinical,MEK inhibitor,targeted cancer,18
amtolmetin-guacil,COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,0,Launched,cyclooxygenase inhibitor,noncancer,49
nedaplatin,N[Pt++]1(N)OCC(=O)O1,0,Launched,DNA inhibitor,chemo,7
sasapyrine,OC(=O)c1ccccc1OC(=O)c1ccccc1O,0,Launched,NFkB pathway inhibitor,noncancer,19
cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,0,Launched,dopamine receptor agonist,noncancer,52
luliconazole,Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer,88
fluticasone-propionate,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,1,Launched,glucocorticoid receptor agonist,noncancer,58
albuterol,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,0,Launched,adrenergic receptor agonist,noncancer,32
carprofen,CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21,0,Launched,cyclooxygenase inhibitor,noncancer,49
scriptaid,ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23,1,Preclinical,HDAC inhibitor,targeted cancer,14
guanaben-acetate,NC(=N)N\N=C\c1c(Cl)cccc1Cl,0,Launched,adrenergic receptor agonist,noncancer,32
fexofenadine,CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,0,Launched,histamine receptor antagonist,noncancer,63
enoximone,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,1,Launched,phosphodiesterase inhibitor,noncancer,76
estriol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O,0,Launched,estrogen receptor agonist,noncancer,56
piperidolate,CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
tamsulosin,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O,0,Launched,adrenergic receptor antagonist,noncancer,33
lacidipine,CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,0,Launched,calcium channel blocker,noncancer,45
methoxsalen,COc1c2occc2cc2ccc(=O)oc12,0,Launched,DNA synthesis inhibitor,noncancer,9
fluroxene,FC(F)(F)COC=C,1,Preclinical,local anesthetic,noncancer,66
diperodon,O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1,0,Preclinical,local anesthetic,noncancer,66
parthenolide-(-),C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,1,Preclinical,NFkB pathway inhibitor,targeted cancer,19
valethamate,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
GR-103691,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,0,Preclinical,dopamine receptor antagonist,noncancer,53
tiquizium,C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1,0,Launched,acetylcholine receptor antagonist,noncancer,28
balsalazide,OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
dienestrol,C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C,0,Launched,estrogen receptor agonist,noncancer,56
VX-222,C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C,0,Phase 2,HCV inhibitor,noncancer,13
dronedarone,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,1,Launched,adrenergic receptor antagonist,noncancer,33
CCT129202,CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1,1,Preclinical,Aurora kinase inhibitor,targeted cancer,3
GSK1070916,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,1,Phase 1,Aurora kinase inhibitor,targeted cancer,3
BRL-50481,CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,0,Preclinical,phosphodiesterase inhibitor,noncancer,76
UB-165,Clc1ccc(cn1)C1=CCCC2CCC1N2,0,Preclinical,acetylcholine receptor agonist,noncancer,27
CGS-15943,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,1,Preclinical,adenosine receptor antagonist,noncancer,31
10-hydroxycamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O,1,Preclinical,topoisomerase inhibitor,Unknown,90
etofenamate,OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer,49
methocarbamol,COc1ccccc1OCC(O)COC(N)=O,1,Launched,muscle relaxant,noncancer,71
moexipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
zilpaterol,CC(C)N[C@H]1CCn2c(O)nc3cccc([C@@H]1O)c23,0,Launched,adrenergic receptor agonist,noncancer,32
INCB-003284,COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,0,Phase 2,CC chemokine receptor antagonist,Unknown,4
ipidacrine,Nc1c2CCCc2nc2CCCCc12,0,Phase 3,acetylcholinesterase inhibitor,noncancer,29
ku-0063794,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1,1,Preclinical,mTOR inhibitor,targeted cancer,67
piketoprofen,CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
levomequitazine,C(C1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12,0,Phase 2,histamine receptor antagonist,noncancer,63
amfepramone,CCN(CC)C(C)C(=O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer,32
alfadolone-acetate,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,0,Phase 2,benzodiazepine receptor agonist,noncancer,44
ZM-447439,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,1,Preclinical,Aurora kinase inhibitor,targeted cancer,3
nicardipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1,0,Launched,calcium channel blocker,noncancer,45
FK-33-824,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O,0,Phase 2,opioid receptor agonist,noncancer,73
DFB,Fc1cccc(c1)\C=N\N=C\c1cccc(F)c1,0,Preclinical,glutamate receptor agonist,noncancer,59
balapiravir,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],1,Phase 2,RNA polymerase inhibitor,noncancer,24
licochalcone-a,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,1,Phase 3,topoisomerase inhibitor,targeted cancer,90
SD-208,Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1,0,Preclinical,TGF beta receptor inhibitor,noncancer,25
chlorphenamine,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer,63
sesamin,C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1,0,Preclinical,NFkB pathway inhibitor,noncancer,19
TAK-715,CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1,1,Phase 2,p38 MAPK inhibitor,noncancer,75
fenbendazole,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,1,Launched,tubulin polymerization inhibitor,noncancer,91
quipazine,C1CN(CCN1)c1ccc2ccccc2n1,0,Preclinical,serotonin receptor agonist,noncancer,85
traxoprodil,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1,0,Phase 2,glutamate receptor antagonist,noncancer,60
bacampicillin,CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
clinafloxacin,NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1,0,Phase 3,bacterial DNA gyrase inhibitor,noncancer,41
CB-03-01,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO,0,Phase 3,androgen receptor antagonist,noncancer,34
SCMC-Lys,N[C@@H](CSCC(O)=O)C(O)=O,0,Launched,mucolytic agent,Unknown,70
oxibendazole,CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1,1,Launched,tubulin polymerization inhibitor,noncancer,91
resminostat,CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO,1,Phase 2,HDAC inhibitor,targeted cancer,14
BRL-54443,CN1CCC(CC1)c1c[nH]c2ccc(O)cc12,0,Preclinical,serotonin receptor agonist,noncancer,85
SB-218795,COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1,1,Preclinical,tachykinin antagonist,noncancer,89
rizatriptan,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,0,Launched,serotonin receptor agonist,noncancer,85
SR-95639A,C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1,0,Preclinical,acetylcholine receptor agonist,noncancer,27
ketoconazole,CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer,88
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1,1,Preclinical,serotonin receptor antagonist,noncancer,86
adrafinil,ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer,32
pirenzepine,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,0,Launched,acetylcholine receptor antagonist,noncancer,28
erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,0,Launched,NFkB pathway inhibitor,noncancer,19
ICI-162846,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,1,Phase 1,histamine receptor antagonist,noncancer,63
quinestrol,C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C,0,Launched,estrogen receptor agonist,noncancer,56
ICI-199441,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer,73
dicycloverine,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,1,Launched,acetylcholine receptor antagonist,noncancer,28
SPP301,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1,0,Phase 3,endothelin receptor antagonist,noncancer,55
MK-0752,OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,0,Phase 1/Phase 2,gamma secretase inhibitor,targeted cancer,57
asaraldehyde,COc1cc(OC)c(C=O)cc1OC,0,Preclinical,cyclooxygenase inhibitor,noncancer,49
sorbitol,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,Launched,mucolytic agent,noncancer,70
nialamide,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,0,Withdrawn,monoamine oxidase inhibitor,noncancer,69
CR8-(R),CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1,1,Preclinical,CDK inhibitor,Unknown,5
nicergoline,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,0,Launched,adrenergic receptor antagonist,noncancer,33
bilobalide,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)C123,0,Preclinical,GABA receptor modulator,noncancer,12
ABT-239,C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N,0,Phase 1,histamine receptor antagonist,noncancer,63
SB-203580,CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,0,Preclinical,p38 MAPK inhibitor,noncancer,75
acrivastine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1,0,Launched,histamine receptor antagonist,noncancer,63
josamycin,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
AZD2461,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,1,Phase 1,PARP inhibitor,targeted cancer,20
eticlopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC,0,Preclinical,dopamine receptor antagonist,noncancer,53
acetylcholine,CC(=O)OCC[N+](C)(C)C,0,Launched,acetylcholine receptor agonist,noncancer,27
chlorogenic-acid,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O,1,Launched,antioxidant,noncancer,37
atazanavir,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,0,Launched,HIV protease inhibitor,noncancer,15
spiroxatrine,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,0,Preclinical,serotonin receptor antagonist,noncancer,86
nifekalant,Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O,0,Launched,potassium channel blocker,noncancer,78
etilefrine,CCNCC(O)c1cccc(O)c1,0,Launched,adrenergic receptor agonist,noncancer,32
clofoctol,CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1,1,Launched,protein synthesis inhibitor,noncancer,81
cilnidipine,COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,0,Launched,calcium channel blocker,noncancer,45
tadalafil,CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O,0,Launched,phosphodiesterase inhibitor,noncancer,76
hexachlorophene,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,1,Launched,potassium channel activator,Unknown,77
thioproperazine,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,1,Launched,dopamine receptor antagonist,noncancer,53
tacedinaline,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N,1,Phase 3,HDAC inhibitor,targeted cancer,14
GS-39783,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,1,Preclinical,GABA receptor modulator,noncancer,12
tosufloxacin,NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
eslicarbazepine-acetate,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12,0,Launched,sodium channel blocker,noncancer,87
YS-035,COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,0,Preclinical,calcium channel blocker,noncancer,45
ADD-233089,Clc1ccc(cc1)N1CC(=NC1=O)N1CCOCC1,0,Phase 1,benzodiazepine receptor agonist,noncancer,44
amthamine,Cc1nc(N)sc1CCN,0,Preclinical,histamine receptor agonist,noncancer,62
naringin-dihydrochalcone,C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,0,Preclinical,cytochrome P450 inhibitor,noncancer,50
clevudine,Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O,0,Launched,DNA polymerase inhibitor,noncancer,8
benperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,0,Launched,dopamine receptor antagonist,noncancer,53
GR46611,COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1,0,Preclinical,serotonin receptor agonist,noncancer,85
pentylenetetrazol,C1CCc2nnnn2CC1,0,Withdrawn,GABA receptor antagonist,noncancer,11
tedizolid-phosphate,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O,1,Launched,protein synthesis inhibitor,noncancer,81
crizotinib,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,1,Launched,ALK tyrosine kinase receptor inhibitor,targeted cancer,1
lafutidine,O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,1,Launched,histamine receptor antagonist,noncancer,63
droxinostat,Cc1cc(Cl)ccc1OCCCC(=O)NO,0,Preclinical,HDAC inhibitor,noncancer,14
SB-202190,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,0,Preclinical,p38 MAPK inhibitor,targeted cancer,75
arecaidine-but-2-ynyl-ester,CC#CCOC(=O)C1=CCCN(C)C1,0,Preclinical,acetylcholine receptor agonist,noncancer,27
GR125487,COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,0,Preclinical,serotonin receptor antagonist,noncancer,86
SB-590885,CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1,1,Preclinical,RAF inhibitor,targeted cancer,23
siguazodan,CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C,0,Phase 1,phosphodiesterase inhibitor,noncancer,76
zafirlukast,COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C,0,Launched,leukotriene receptor antagonist,noncancer,65
baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,1,Phase 3,JAK inhibitor,noncancer,17
SLV-320,O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1,0,Phase 2,adenosine receptor antagonist,Unknown,31
flopropione,CCC(=O)c1c(O)cc(O)cc1O,0,Launched,serotonin receptor antagonist,noncancer,86
org-9768,CC1(CN)Cc2ccccc2C1,0,Phase 1,adrenergic receptor antagonist,noncancer,33
tryptanthrin,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,1,Preclinical,cyclooxygenase inhibitor,targeted cancer,49
oxyphenonium,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,0,Launched,cholinergic receptor antagonist,noncancer,48
nomegestrol-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,1,Launched,progesterone receptor agonist,noncancer,79
isopropamide-iodide,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer,28
copanlisib,COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12,0,Launched,PI3K inhibitor,targeted cancer,21
SB-203186,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,0,Preclinical,serotonin receptor antagonist,noncancer,86
KRN-633,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,0,Preclinical,VEGFR inhibitor,targeted cancer,26
retapamulin,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C,0,Launched,protein synthesis inhibitor,noncancer,81
propylhexedrine,CNC(C)CC1CCCCC1,0,Launched,adrenergic receptor agonist,noncancer,32
tiaprofenic-acid,CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
roscovitine,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,Phase 2,CDK inhibitor,targeted cancer,5
PIK-293,Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O,0,Preclinical,PI3K inhibitor,targeted cancer,21
alisertib,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,1,Phase 3,Aurora kinase inhibitor,targeted cancer,3
deflazacort,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,1,Launched,glucocorticoid receptor agonist,noncancer,58
danoprevir,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1,0,Phase 2,HCV inhibitor,noncancer,13
milacemide,CCCCCNCC(N)=O,0,Phase 3,monoamine oxidase inhibitor,noncancer,69
otilonium,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC,0,Launched,acetylcholine receptor antagonist,noncancer,28
abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,1,Launched,CDK inhibitor,targeted cancer,5
L-161982,CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C,0,Preclinical,prostanoid receptor antagonist,noncancer,80
ibuprofen,CC(C)Cc1ccc(cc1)C(C)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
hypoxanthine,O=c1[nH]cnc2nc[nH]c12,0,Preclinical,PARP inhibitor,noncancer,20
GW-583340,CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1,Preclinical,EGFR inhibitor,targeted cancer,10
azalomycin-b,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,1,Preclinical,bacterial 50S ribosomal subunit inhibitor,Unknown,40
brompheniramine,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer,63
tebipenem,C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
rosoxacin,CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1,0,Launched,topoisomerase inhibitor,noncancer,90
AZD8931,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,1,Phase 2,EGFR inhibitor,targeted cancer,10
flunixin-meglumin,Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F,0,Launched,prostanoid receptor antagonist,Unknown,80
mCPP,Clc1cccc(c1)N1CCNCC1,0,Phase 2,serotonin receptor agonist,noncancer,85
XL-147,Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1,0,Phase 2,PI3K inhibitor,targeted cancer,21
sulfadiazine,Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1,0,Launched,bacterial antifolate,noncancer,42
lerisetron,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,1,Phase 3,serotonin receptor antagonist,noncancer,86
RS-79948,CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12,0,Preclinical,adrenergic receptor antagonist,noncancer,33
LY2140023,N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,0,Phase 3,glutamate receptor agonist,noncancer,59
cytisine,O=c1cccc2[C@H]3CNC[C@H](C3)Cn12,0,Launched,acetylcholine receptor agonist,noncancer,27
blonanserin,CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
perospirone,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,Launched,RNA polymerase inhibitor,noncancer,24
prenylamine,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,0,Withdrawn,calcium channel blocker,noncancer,45
bopindolol,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,0,Launched,adrenergic receptor antagonist,noncancer,33
chlorambucil,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,1,Launched,DNA inhibitor,chemo,7
UNC0321,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
sulfamonomethoxine,COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1,0,Launched,bacterial antifolate,noncancer,42
remimazolam,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12,0,Phase 3,benzodiazepine receptor agonist,noncancer,44
ZM-323881,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,0,Preclinical,VEGFR inhibitor,targeted cancer,26
cefetamet-pivoxil,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
Ro-20-1724,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,0,Preclinical,phosphodiesterase inhibitor,noncancer,76
A-366,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
ceftriaxone,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
pipamperone,NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1,0,Launched,dopamine receptor antagonist,noncancer,53
repsox,Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1,1,Preclinical,TGF beta receptor inhibitor,noncancer,25
"1-(1,2-Diphenylethyl)piperidine-(+/-)",C(C(N1CCCCC1)c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor antagonist,noncancer,60
sirolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O,1,Launched,mTOR inhibitor,noncancer,67
tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,1,Phase 2,EGFR inhibitor,targeted cancer,10
anisotropine,CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C,0,Launched,acetylcholine receptor antagonist,noncancer,28
paraxanthine,Cn1cnc2[nH]c(=O)n(C)c(=O)c12,0,Phase 1,adenosine receptor antagonist,noncancer,31
nalmefene,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O,0,Launched,opioid receptor antagonist,noncancer,74
icotinib,C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,1,Launched,EGFR inhibitor,targeted cancer,10
propantheline,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer,28
dimaprit,CN(C)CCCSC(N)=N,0,Preclinical,histamine receptor agonist,noncancer,62
irinotecan,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12,1,Launched,topoisomerase inhibitor,chemo,90
BW-373U86,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1,0,Preclinical,opioid receptor agonist,noncancer,73
palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O,1,Launched,CDK inhibitor,targeted cancer,5
NVP-AUY922,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,1,Phase 2,HSP inhibitor,targeted cancer,16
preclamol,CCCN1CCC[C@@H](C1)c1cccc(O)c1,0,Phase 2,dopamine receptor agonist,noncancer,52
3-deazaneplanocin-A,Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
fusidic-acid,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
clofibric-acid,CC(C)(Oc1ccc(Cl)cc1)C(O)=O,0,Launched,PPAR receptor agonist,noncancer,22
alcuronium,OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21,0,Launched,muscle relaxant,noncancer,71
PIK-93,CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO,0,Preclinical,PI3K inhibitor,targeted cancer,21
benidipine,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1,0,Launched,calcium channel blocker,noncancer,45
everolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO,1,Launched,mTOR inhibitor,targeted cancer,67
amiodarone,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,0,Launched,potassium channel blocker,noncancer,78
altretamine,CN(C)c1nc(nc(n1)N(C)C)N(C)C,1,Launched,DNA synthesis inhibitor,chemo,9
chlorhexidine,Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,1,Launched,membrane integrity inhibitor,noncancer,68
firocoxib,CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O,0,Launched,cyclooxygenase inhibitor,Unknown,49
bromfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer,49
tracazolate,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,0,Phase 2,GABA receptor modulator,noncancer,12
tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,0,Launched,JAK inhibitor,noncancer,17
PNU-142633,CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1,0,Phase 2,serotonin receptor agonist,noncancer,85
HA-1004,NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12,0,Phase 2,calcium channel blocker,noncancer,45
mafenide,NCc1ccc(cc1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer,46
GR-79236,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12,0,Phase 1,adenosine receptor agonist,noncancer,30
perampanel,O=c1c(cc(cn1-c1ccccc1)-c1ccccn1)-c1ccccc1C#N,0,Launched,glutamate receptor antagonist,noncancer,60
vinburnine,CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41,0,Launched,adrenergic receptor antagonist,noncancer,33
idazoxan,C1CN=C(N1)C1COc2ccccc2O1,1,Phase 3,adrenergic receptor antagonist,noncancer,33
lidoflazine,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,0,Launched,calcium channel blocker,noncancer,45
pivmecillinam,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
SCH-58261,Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1,1,Preclinical,adenosine receptor antagonist,noncancer,31
promethazine,CC(CN1c2ccccc2Sc2ccccc12)N(C)C,0,Launched,histamine receptor antagonist,noncancer,63
LY2784544,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,1,Phase 2,JAK inhibitor,noncancer,17
BYK-204165,Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12,0,Preclinical,PARP inhibitor,noncancer,20
neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,1,Phase 3,EGFR inhibitor,targeted cancer,10
tobramycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
tanespimycin,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O,1,Phase 3,HSP inhibitor,targeted cancer,16
thiazovivin,O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1,0,Preclinical,rho associated kinase inhibitor,noncancer,84
nimesulide,CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
ICI-63197,CCCn1c2nc(N)nn2cc(C)c1=O,0,Preclinical,phosphodiesterase inhibitor,noncancer,76
flumethasone-pivalate,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,1,Launched,glucocorticoid receptor agonist,noncancer,58
phenazopyridine,Nc1ccc(\N=N\c2ccccc2)c(N)n1,0,Launched,local anesthetic,noncancer,66
deserpidine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
GABA-linoleamide,CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O,0,Phase 2,benzodiazepine receptor agonist,Unknown,44
bunazosin,CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,0,Launched,adrenergic receptor antagonist,noncancer,33
taxifolin,O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1,0,Phase 2,opioid receptor antagonist,noncancer,74
HTMT,CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer,62
ADL5859,CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12,1,Phase 2,opioid receptor agonist,noncancer,73
dacinostat,OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1,1,Phase 1,HDAC inhibitor,Unknown,14
A-674563,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,1,Preclinical,AKT inhibitor,Unknown,0
BNC105,COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O,1,Phase 2,tubulin polymerization inhibitor,chemo,91
SNX-2112,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,1,Phase 1,HSP inhibitor,Unknown,16
trepibutone,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,0,Launched,cholinergic receptor antagonist,noncancer,48
amfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,1,Launched,cyclooxygenase inhibitor,noncancer,49
eltoprazine,C1CN(CCN1)c1cccc2OCCOc12,0,Phase 2,serotonin receptor agonist,noncancer,85
ME0328,CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,0,Preclinical,PARP inhibitor,targeted cancer,20
metoclopramide,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
pirlindole,Cc1ccc2n3CCNC4CCCc(c34)c2c1,0,Launched,monoamine oxidase inhibitor,noncancer,69
AMG-319,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,0,Phase 2,PI3K inhibitor,targeted cancer,21
isradipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C,0,Launched,calcium channel blocker,noncancer,45
amineptine,OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12,0,Withdrawn,dopamine receptor agonist,noncancer,52
entinostat,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,1,Phase 3,HDAC inhibitor,targeted cancer,14
BGT226,COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1,1,Phase 1/Phase 2,PI3K inhibitor,Unknown,21
EMD-53998,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,1,Phase 1,phosphodiesterase inhibitor,noncancer,76
FGIN-1-43,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1,0,Preclinical,benzodiazepine receptor agonist,noncancer,44
EPZ-5676,CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1,1,Phase 1,histone lysine methyltransferase inhibitor,targeted cancer,64
desogestrel,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,0,Launched,progesterone receptor agonist,noncancer,79
PF-03814735,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21,1,Phase 1,Aurora kinase inhibitor,targeted cancer,3
amrinone,Nc1cc(c[nH]c1=O)-c1ccncc1,0,Launched,phosphodiesterase inhibitor,noncancer,76
dichlorvos,COP(=O)(OC)OC=C(Cl)Cl,1,Launched,acetylcholinesterase inhibitor,noncancer,29
cinflumide,Fc1cccc(c1)\C=C\C(=O)NC1CC1,0,Phase 2,muscle relaxant,noncancer,71
ruxolitinib-(S),N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,0,Preclinical,JAK inhibitor,targeted cancer,17
ocinaplon,O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1,0,Phase 3,GABA receptor modulator,noncancer,12
piroximone,CCc1[nH]c(O)nc1C(=O)c1ccncc1,0,Phase 2,phosphodiesterase inhibitor,noncancer,76
imidapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,1,Launched,angiotensin converting enzyme inhibitor,noncancer,35
pipotiazine-palmitate,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
PD-184352,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,1,Phase 2,MEK inhibitor,targeted cancer,18
miltefosine,CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C,0,Launched,membrane integrity inhibitor,noncancer,68
trientine,NCCNCCNCCN,0,Launched,chelating agent,noncancer,47
isoxsuprine,CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer,32
ryuvidine,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O,1,Preclinical,histone lysine methyltransferase inhibitor,noncancer,64
PNU-22394,Cn1c2CCNCCc2c2ccccc12,0,Phase 2,serotonin receptor agonist,noncancer,85
merbarone,O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O,0,Phase 2,topoisomerase inhibitor,chemo,90
pinocembrin,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1,0,Phase 2,cytochrome P450 inhibitor,targeted cancer,50
MRS3777,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12,0,Preclinical,adenosine receptor antagonist,noncancer,31
ranolazine,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,0,Launched,sodium channel blocker,noncancer,87
diphemanil,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer,28
AZD6482,C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1,1,Phase 1,PI3K inhibitor,targeted cancer,21
mabuterol,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F,0,Launched,adrenergic receptor agonist,noncancer,32
carbinoxamine,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer,63
ercalcitriol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Phase 1,vitamin D receptor agonist,noncancer,92
iproniazid,CC(C)NNC(=O)c1ccncc1,1,Withdrawn,monoamine oxidase inhibitor,noncancer,69
JNJ-37822681,Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F,0,Phase 2,dopamine receptor antagonist,noncancer,53
salvinorin-a,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,1,Phase 1,opioid receptor agonist,noncancer,73
temazepam,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,1,Withdrawn,benzodiazepine receptor agonist,noncancer,44
chlorphenesin,OCC(O)COc1ccc(Cl)cc1,0,Launched,muscle relaxant,noncancer,71
BAY-11-7082,Cc1ccc(cc1)S(=O)(=O)\C=C\C#N,1,Preclinical,NFkB pathway inhibitor,noncancer,19
aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,1,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
tolonidine,Cc1ccc(NC2=NCCN2)c(Cl)c1,0,Launched,adrenergic receptor antagonist,noncancer,33
tiracizine,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1,0,Withdrawn,sodium channel blocker,noncancer,87
nalidixic-acid,CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
teneligliptin,Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1,0,Launched,dipeptidyl peptidase inhibitor,noncancer,51
YM-201636,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,1,Preclinical,PI3K inhibitor,targeted cancer,21
tetrandrine,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,1,Preclinical,calcium channel blocker,targeted cancer,45
desloratadine,Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1,0,Launched,histamine receptor antagonist,noncancer,63
pazufloxacin,C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1,0,Launched,topoisomerase inhibitor,noncancer,90
ronidazole,Cn1c(COC(N)=O)ncc1[N+]([O-])=O,0,Launched,antiprotozoal agent,noncancer,38
AP26113,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,1,Phase 2,ALK tyrosine kinase receptor inhibitor,targeted cancer,1
carazolol,CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,0,Launched,adrenergic receptor antagonist,noncancer,33
homoquinolinic-acid,OC(=O)Cc1cccnc1C(O)=O,1,Preclinical,glutamate receptor agonist,noncancer,59
amodiaquine,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,0,Launched,histamine receptor agonist,Unknown,62
isoxicam,CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O,0,Withdrawn,cyclooxygenase inhibitor,noncancer,49
LY2090314,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,1,Phase 2,glycogen synthase kinase inhibitor,targeted cancer,61
asenapine,CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
sulfanilamide,Nc1ccc(cc1)S(N)(=O)=O,1,Launched,carbonic anhydrase inhibitor,noncancer,46
gepefrine,CC(N)Cc1cccc(O)c1,0,Launched,adrenergic receptor agonist,noncancer,32
barasertib,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,1,Phase 2/Phase 3,Aurora kinase inhibitor,targeted cancer,3
amcinonide,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,0,Launched,glucocorticoid receptor agonist,noncancer,58
S-111,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,0,Phase 2,PARP inhibitor,targeted cancer,20
homatropine-methylbromide,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1,0,Launched,acetylcholine receptor antagonist,Unknown,28
7-nitroindazole,[O-][N+](=O)c1cccc2cn[nH]c12,1,Preclinical,nitric oxide synthase inhibitor,noncancer,72
UNC0646,COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
A-803467,COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1,1,Preclinical,sodium channel blocker,noncancer,87
BRL-37344,C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,0,Phase 2,adrenergic receptor agonist,noncancer,32
betamethasone-acetate,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,0,Launched,glucocorticoid receptor agonist,noncancer,58
PU-H71,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,1,Phase 1,HSP inhibitor,Unknown,16
TCS2002,Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1,0,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
cortisone,C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer,58
geniposidic-acid,OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O,0,Preclinical,cyclooxygenase inhibitor,noncancer,49
enalapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
dinaciclib,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,1,Phase 3,CDK inhibitor,Unknown,5
ferulic-acid,COc1cc(\C=C\C(O)=O)ccc1O,0,Phase 2,antioxidant,noncancer,37
clenbuterol,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,1,Launched,adrenergic receptor agonist,noncancer,32
BIX-01294,COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F,1,Launched,RAF inhibitor,targeted cancer,23
talarozole,CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1,0,Phase 2,cytochrome P450 inhibitor,noncancer,50
indoramin,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,0,Launched,adrenergic receptor antagonist,noncancer,33
GDC-0068,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,1,Phase 2,AKT inhibitor,targeted cancer,0
olmesartan-medoxomil,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,0,Launched,angiotensin receptor antagonist,Unknown,36
TGR-1202,CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12,0,Phase 3,PI3K inhibitor,targeted cancer,21
pindolol,CC(C)NCC(O)COc1cccc2[nH]ccc12,1,Launched,adrenergic receptor antagonist,noncancer,33
rifampin,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C,1,Launched,RNA polymerase inhibitor,noncancer,24
ramosetron,Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12,0,Launched,serotonin receptor antagonist,noncancer,86
WAY-200070,Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1,0,Preclinical,estrogen receptor agonist,noncancer,56
pancuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer,28
alpha-tochopheryl-acetate,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1,0,Launched,antioxidant,noncancer,37
beclomethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer,58
butaclamol,CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34,0,Phase 2,dopamine receptor antagonist,noncancer,53
emedastine,CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1,0,Launched,histamine receptor antagonist,noncancer,63
adefovir,Nc1ncnc2n(CCOCP(O)(O)=O)cnc12,0,Launched,DNA polymerase inhibitor,noncancer,8
YO-01027,C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O,1,Preclinical,gamma secretase inhibitor,noncancer,57
diclofenac,OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,0,Launched,cyclooxygenase inhibitor,noncancer,49
iohexol,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,Unknown,82
MDL-11939,OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1,0,Phase 2,serotonin receptor antagonist,noncancer,86
bedaquiline,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,0,Launched,ATPase inhibitor,noncancer,2
AS-77,O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,0,Preclinical,potassium channel blocker,noncancer,78
droperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O,0,Launched,dopamine receptor antagonist,noncancer,53
buparvaquone,CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1,0,Launched,antiprotozoal agent,noncancer,38
idalopirdine,FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1,0,Phase 3,serotonin receptor antagonist,noncancer,86
tetracaine,CCCCNc1ccc(cc1)C(=O)OCCN(C)C,0,Launched,membrane integrity inhibitor,noncancer,68
dizocilpine-(+),C[C@]12N[C@H](Cc3ccccc13)c1ccccc21,0,Preclinical,glutamate receptor antagonist,noncancer,60
levo-phencynonate,CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
AZD1480,C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1,1,Phase 1,JAK inhibitor,targeted cancer,17
olomoucine,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12,0,Preclinical,CDK inhibitor,targeted cancer,5
oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
eglumetad,N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,0,Phase 2,glutamate receptor agonist,noncancer,59
setiptiline,CN1CCC2=C(C1)c1ccccc1Cc1ccccc21,0,Launched,adrenergic receptor antagonist,Unknown,33
1-phenylbiguanide,NC(=N)NC(=N)Nc1ccccc1,1,Preclinical,serotonin receptor agonist,noncancer,85
NSC-9965,CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1,0,Preclinical,acetylcholine receptor antagonist,noncancer,28
thonzonium,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1,1,Launched,ATPase inhibitor,noncancer,2
SDM25N,CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O,0,Preclinical,opioid receptor antagonist,noncancer,74
bicyclol,COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO,0,Launched,NFkB pathway inhibitor,noncancer,19
eperezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1,0,Phase 1,bacterial 30S ribosomal subunit inhibitor,Unknown,39
LY255283,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1,0,Preclinical,leukotriene receptor antagonist,noncancer,65
captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
GW-1929,CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,0,Preclinical,PPAR receptor agonist,noncancer,22
5-iodo-A-85380,Ic1cncc(OC[C@@H]2CCN2)c1,0,Phase 2,acetylcholine receptor agonist,noncancer,27
verubulin,COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12,1,Phase 2,tubulin polymerization inhibitor,chemo,91
secalciferol,C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C,0,Launched,vitamin D receptor agonist,noncancer,92
isepamicin,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O,0,Launched,protein synthesis inhibitor,noncancer,81
PHCCC,O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1,0,Preclinical,glutamate receptor agonist,targeted cancer,59
bicuculline-methochloride-(-),C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21,0,Preclinical,GABA receptor antagonist,noncancer,11
adefovir-dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C,1,Launched,DNA polymerase inhibitor,noncancer,8
azaperone,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1,0,Launched,dopamine receptor antagonist,noncancer,53
mesulergine,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,0,Phase 2,dopamine receptor agonist,noncancer,52
phenothiazine,N1c2ccccc2Sc2ccccc12,0,Preclinical,dopamine receptor antagonist,noncancer,53
cyclopiazonic-acid,CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O,0,Preclinical,ATPase inhibitor,noncancer,2
RS-100329,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,0,Preclinical,adrenergic receptor antagonist,noncancer,33
donitriptan,NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12,0,Phase 2,serotonin receptor agonist,noncancer,85
quinapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
MF-101,Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1,0,Phase 3,estrogen receptor agonist,targeted cancer,56
naproxen,COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O,1,Launched,cyclooxygenase inhibitor,noncancer,49
azasetron,CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2,0,Launched,serotonin receptor antagonist,noncancer,86
streptomycin,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
oxprenolol,CC(C)NCC(O)COc1ccccc1OCC=C,1,Launched,adrenergic receptor antagonist,noncancer,33
PCI-34051,COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1,0,Preclinical,HDAC inhibitor,targeted cancer,14
indiplon,CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1,1,Phase 3,benzodiazepine receptor agonist,noncancer,44
N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12,0,Preclinical,adenosine receptor agonist,Unknown,30
cephalosporin-c-zn,CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O,0,Preclinical,bacterial cell wall synthesis inhibitor,noncancer,43
cetirizine,OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer,63
digitoxin,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,1,Launched,ATPase inhibitor,Unknown,2
priralfinamide,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,0,Phase 3,sodium channel blocker,noncancer,87
cefoselis,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
proquazone,CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
etazolate,CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C,0,Phase 2,phosphodiesterase inhibitor,targeted cancer,76
esculin,OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O,0,Phase 1,antioxidant,targeted cancer,37
GW-0742,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F,0,Preclinical,PPAR receptor agonist,noncancer,22
L-NIL,CC(=N)NCCCC[C@H](N)C(O)=O,0,Preclinical,nitric oxide synthase inhibitor,noncancer,72
oxotremorine-m,C[N+](C)(C)CC#CCN1CCCC1=O,0,Preclinical,acetylcholine receptor agonist,noncancer,27
LE-135,CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C,1,Preclinical,retinoid receptor agonist,noncancer,83
buclizine,CC(C)(C)c1ccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)cc1,0,Launched,histamine receptor antagonist,noncancer,63
romidepsin,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,1,Launched,HDAC inhibitor,Unknown,14
lornoxicam,CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
pheniramine,CN(C)CCC(c1ccccc1)c1ccccn1,1,Launched,histamine receptor antagonist,noncancer,63
ipsapirone,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,1,Phase 3,serotonin receptor agonist,noncancer,85
methscopolamine,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer,28
clidinium,C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
ajmaline,CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,1,Launched,sodium channel blocker,noncancer,87
trolox,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,1,Launched,antioxidant,noncancer,37
lapatinib,CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1,Launched,EGFR inhibitor,targeted cancer,10
8-hydroxy-DPAT,CCCN(CCC)C1CCc2cccc(O)c2C1,0,Preclinical,serotonin receptor agonist,noncancer,85
pibenzimol,c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1,1,Phase 2,DNA inhibitor,targeted cancer,7
pridinol,OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1,0,Launched,muscle relaxant,noncancer,71
BW-180C,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,1,Phase 2,opioid receptor agonist,noncancer,73
R-1479,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1,0,Phase 1,HCV inhibitor,noncancer,13
vildagliptin,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N,0,Launched,dipeptidyl peptidase inhibitor,noncancer,51
CGP-54626,C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,1,Preclinical,GABA receptor antagonist,noncancer,11
levalbuterol,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,0,Launched,adrenergic receptor agonist,noncancer,32
cefixime,Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
PMPA,OC(=O)CCC(CP(O)(O)=O)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
limonin,CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1,0,Preclinical,HIV protease inhibitor,targeted cancer,15
sulfaguanidine,NC(=N)NS(=O)(=O)c1ccc(N)cc1,0,Launched,bacterial antifolate,noncancer,42
A61603,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,1,Preclinical,adrenergic receptor agonist,noncancer,32
histamine,NCCc1c[nH]cn1,0,Launched,histamine receptor agonist,noncancer,62
prednisolone-sodium-phosphate,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O,0,Launched,glucocorticoid receptor agonist,noncancer,58
UNC0631,COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
SKF-81297,Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1,0,Preclinical,dopamine receptor agonist,noncancer,52
ciprofloxacin,OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
raclopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,1,Launched,dopamine receptor antagonist,noncancer,53
aminoguanidine,NNC(N)=N,0,Phase 3,nitric oxide synthase inhibitor,noncancer,72
clorgiline,CN(CCCOc1ccc(Cl)cc1Cl)CC#C,0,Phase 2,monoamine oxidase inhibitor,Unknown,69
darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0,Launched,HIV protease inhibitor,noncancer,15
urapidil,COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,0,Launched,adrenergic receptor antagonist,noncancer,33
diloxanide,CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1,0,Launched,protein synthesis inhibitor,noncancer,81
rucaparib,CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23,0,Phase 3,PARP inhibitor,targeted cancer,20
picolinic-acid,O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1,1,Phase 2,chelating agent,noncancer,47
garenoxacin,C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1,0,Launched,topoisomerase inhibitor,noncancer,90
estradiol-valerate,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,0,Launched,estrogen receptor agonist,targeted cancer,56
U-0124,CS\C(N)=C(C#N)\C(C#N)=C(/N)SC,0,Preclinical,MEK inhibitor,noncancer,18
practolol,CC(C)NCC(O)COc1ccc(NC(C)=O)cc1,1,Withdrawn,adrenergic receptor antagonist,noncancer,33
AZD2858,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
SNX-5422,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1,1,Phase 1/Phase 2,HSP inhibitor,Unknown,16
cleviprex,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC,0,Launched,calcium channel blocker,noncancer,45
acetazolamide,CC(=O)Nc1nnc(s1)S(N)(=O)=O,1,Launched,carbonic anhydrase inhibitor,noncancer,46
XL388,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,1,Preclinical,mTOR inhibitor,targeted cancer,67
oxcarbazepine,NC(=O)N1c2ccccc2CC(=O)c2ccccc12,1,Launched,sodium channel blocker,noncancer,87
pefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
PI3K-IN-2,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,1,Phase 2,PI3K inhibitor,targeted cancer,21
U-104,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,0,Preclinical,carbonic anhydrase inhibitor,targeted cancer,46
Ro-9187,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,1,Preclinical,HCV inhibitor,noncancer,13
WHI-P154,COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC,1,Preclinical,JAK inhibitor,targeted cancer,17
JTC-801,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,1,Phase 2,opioid receptor antagonist,noncancer,74
basimglurant,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,0,Phase 2,glutamate receptor antagonist,noncancer,60
exisulind,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)(=O)=O,0,Phase 3,phosphodiesterase inhibitor,targeted cancer,76
clobenpropit,Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1,0,Preclinical,histamine receptor antagonist,noncancer,63
IEM1460,C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,0,Preclinical,glutamate receptor antagonist,noncancer,60
levobunolol-(+),CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12,0,Preclinical,adrenergic receptor antagonist,noncancer,33
PF-4981517,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,1,Preclinical,cytochrome P450 inhibitor,noncancer,50
schisandrin-b,COc1cc2C[C@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC,0,Preclinical,antioxidant,noncancer,37
idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O,1,Launched,topoisomerase inhibitor,Unknown,90
zofenopril-calcium,C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,1,Launched,cytochrome P450 inhibitor,noncancer,50
rolipram-S(+),COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1,0,Preclinical,phosphodiesterase inhibitor,noncancer,76
N-acetylglycyl-D-glutamic-acid,CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
phenylbutyrate,OC(=O)CCCc1ccccc1,0,Launched,HDAC inhibitor,noncancer,14
chlorzoxazone,Clc1ccc2oc(=O)[nH]c2c1,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
SB-525334,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C,1,Preclinical,TGF beta receptor inhibitor,noncancer,25
sparfloxacin,C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1,1,Withdrawn,bacterial DNA gyrase inhibitor,noncancer,41
magnolol,Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O,0,Preclinical,PPAR receptor agonist,targeted cancer,22
MRS1845,CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,0,Preclinical,calcium channel blocker,noncancer,45
amantadine,NC12CC3CC(CC(C3)C1)C2,0,Launched,glutamate receptor antagonist,noncancer,60
tenidap,NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12,0,Phase 3,cyclooxygenase inhibitor,noncancer,49
ibuprofen-(s),CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O,0,Preclinical,cyclooxygenase inhibitor,noncancer,49
fimasartan,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,Unknown,36
eperisone,CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer,28
melperone,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
zaltoprofen,CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
NU6027,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,1,Preclinical,CDK inhibitor,targeted cancer,5
UNBS-5162,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,1,Phase 1,CC chemokine receptor antagonist,targeted cancer,4
levamisole,C1CN2C[C@@H](N=C2S1)c1ccccc1,0,Withdrawn,acetylcholine receptor agonist,targeted cancer,27
ranitidine,CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O,1,Launched,histamine receptor antagonist,noncancer,63
amperozide,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,0,Launched,dopamine receptor antagonist,noncancer,53
propranolol,CC(C)NCC(O)COc1cccc2ccccc12,1,Launched,adrenergic receptor antagonist,noncancer,33
adenosine-triphosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,0,Phase 2,adenosine receptor agonist,noncancer,30
oxyquinoline,Oc1cccc2cccnc12,1,Launched,chelating agent,noncancer,47
immepip,C(C1CCNCC1)c1c[nH]cn1,0,Preclinical,histamine receptor agonist,Unknown,62
aspirin,CC(=O)Oc1ccccc1C(O)=O,1,Launched,cyclooxygenase inhibitor,noncancer,49
albendazole,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,1,Launched,tubulin polymerization inhibitor,noncancer,91
phenelzine,NNCCc1ccccc1,1,Launched,monoamine oxidase inhibitor,noncancer,69
sertaconazole,Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer,88
WAY-100635,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,0,Phase 1,serotonin receptor antagonist,noncancer,86
nepafenac,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,0,Launched,cyclooxygenase inhibitor,Unknown,49
TTNPB,C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C,0,Phase 1,retinoid receptor agonist,noncancer,83
CHIR-99021,Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl,1,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
cilazapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer,35
saxagliptin,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,1,Launched,dipeptidyl peptidase inhibitor,noncancer,51
celiprolol,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O,0,Launched,adrenergic receptor antagonist,noncancer,33
harmane,Cc1nccc2c3ccccc3[nH]c12,0,Preclinical,monoamine oxidase inhibitor,noncancer,69
paliperidone,Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12,1,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
tyrphostin-AG-494,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,1,Preclinical,EGFR inhibitor,targeted cancer,10
cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,1,Launched,DNA alkylating agent,chemo,6
gadodiamide,CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,0,Launched,radiopaque medium,noncancer,82
palifosfamide,OP(=O)(NCCCl)NCCCl,0,Phase 3,DNA alkylating agent,chemo,6
alfacalcidol,CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer,92
sodium-oxybate,OCCCC(O)=O,0,Launched,benzodiazepine receptor agonist,Unknown,44
alpha-methylhistamine-dihydrobromide-(R)-(-),C[C@@H](N)Cc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer,62
ZK811752,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,1,Phase 2,CC chemokine receptor antagonist,targeted cancer,4
xipamide,Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer,46
cloxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
iniparib,NC(=O)c1ccc(I)c(c1)[N+]([O-])=O,0,Phase 3,PARP inhibitor,targeted cancer,20
ritonavir,CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,0,Launched,HIV protease inhibitor,noncancer,15
trospium,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
mericitabine,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,1,Phase 2,HCV inhibitor,noncancer,13
propacetamol,CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
CUDC-101,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,1,Phase 1,EGFR inhibitor,targeted cancer,10
CYT-997,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,1,Phase 2,tubulin polymerization inhibitor,Unknown,91
tropesin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(C(O)=O)c3ccccc3)c2c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
xamoterol,OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1,0,Phase 3,adrenergic receptor agonist,noncancer,32
oxyphencyclimine,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,1,Launched,cholinergic receptor antagonist,noncancer,48
clebopride,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,1,Launched,dopamine receptor antagonist,noncancer,53
trovafloxacin,N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,1,Withdrawn,bacterial DNA gyrase inhibitor,noncancer,41
gadobutrol,OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,0,Launched,radiopaque medium,noncancer,82
disopyramide,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,0,Launched,sodium channel blocker,noncancer,87
ketorolac,OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
quinolinic-acid,OC(=O)c1cccnc1C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
UBP-302,N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
TWS-119,Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
nilvadipine,COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N,0,Launched,calcium channel blocker,noncancer,45
ethambutol,CC[C@@H](CO)NCCN[C@@H](CC)CO,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
DPCPX,CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCCC1,0,Phase 1,adenosine receptor antagonist,noncancer,31
L-Quisqualic-acid,N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
cinoxacin,CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12,0,Launched,topoisomerase inhibitor,noncancer,90
FERb-033,O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O,1,Preclinical,EGFR inhibitor,targeted cancer,10
3-bromo-7-nitroindazole,[O-][N+](=O)c1cccc2c(Br)n[nH]c12,0,Preclinical,nitric oxide synthase inhibitor,noncancer,72
carteolol,CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,0,Launched,adrenergic receptor antagonist,noncancer,33
TH-302,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,1,Phase 3,DNA alkylating agent,chemo,6
valganciclovir,CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O,0,Launched,DNA synthesis inhibitor,noncancer,9
astemizole,COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,1,Withdrawn,histamine receptor antagonist,noncancer,63
skepinone-l,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,1,Preclinical,p38 MAPK inhibitor,noncancer,75
UH-232-(+),CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,1,Preclinical,dopamine receptor antagonist,noncancer,53
LY2157299,Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O,0,Phase 2/Phase 3,TGF beta receptor inhibitor,targeted cancer,25
suprofen,CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1,0,Withdrawn,cyclooxygenase inhibitor,noncancer,49
BS-181,CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,0,Preclinical,CDK inhibitor,targeted cancer,5
Ro-10-5824,Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1,1,Preclinical,dopamine receptor agonist,noncancer,52
eletriptan,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,0,Launched,serotonin receptor agonist,noncancer,85
clemastine,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer,63
MMPX,COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1,0,Preclinical,phosphodiesterase inhibitor,noncancer,76
simeprevir,COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C,0,Launched,HCV inhibitor,noncancer,13
fananserin,Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1,0,Phase 2,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
pentolinium,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,0,Launched,cholinergic receptor antagonist,noncancer,48
bromopride,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,0,Launched,dopamine receptor antagonist,noncancer,53
dipyridamole,OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO,0,Launched,phosphodiesterase inhibitor,noncancer,76
nafadotride,CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC,0,Preclinical,dopamine receptor antagonist,noncancer,53
1400W,CC(=N)NCc1cccc(CN)c1,0,Preclinical,nitric oxide synthase inhibitor,noncancer,72
ethaverine,CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC,0,Launched,calcium channel blocker,noncancer,45
cinnarazine,C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,1,Launched,calcium channel blocker,noncancer,45
sertindole,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,1,Withdrawn,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
prazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1,1,Launched,adrenergic receptor antagonist,noncancer,33
TG-101209,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,1,Preclinical,JAK inhibitor,noncancer,17
doxazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1,0,Launched,adrenergic receptor antagonist,noncancer,33
telmisartan,CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C,0,Launched,angiotensin receptor antagonist,noncancer,36
sodium-salicylate,OC(=O)c1ccccc1O,0,Launched,prostanoid receptor antagonist,noncancer,80
L-701324,Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12,0,Preclinical,glutamate receptor antagonist,noncancer,60
oxiperomide,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,1,Phase 2,dopamine receptor antagonist,noncancer,53
vercirnon,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1,0,Phase 3,CC chemokine receptor antagonist,noncancer,4
panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1,1,Launched,HDAC inhibitor,Unknown,14
etodolac,CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12,0,Launched,cyclooxygenase inhibitor,noncancer,49
CCT137690,CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1,1,Preclinical,Aurora kinase inhibitor,targeted cancer,3
XL888,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,1,Phase 1,HSP inhibitor,Unknown,16
rolipram,COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1,0,Phase 3,phosphodiesterase inhibitor,noncancer,76
diphenyleneiodonium,[I+]1c2ccccc2-c2ccccc12,1,Preclinical,nitric oxide synthase inhibitor,targeted cancer,72
phenylephrine,CNC[C@H](O)c1cccc(O)c1,0,Launched,adrenergic receptor agonist,noncancer,32
montelukast,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,0,Launched,leukotriene receptor antagonist,noncancer,65
tylosin,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,0,Launched,protein synthesis inhibitor,noncancer,81
chlormezanone,CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O,0,Withdrawn,GABA receptor modulator,noncancer,12
refametinib,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,1,Phase 2,MEK inhibitor,targeted cancer,18
naftopidil,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,0,Launched,adrenergic receptor antagonist,Unknown,33
mesoridazine,CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O,1,Launched,dopamine receptor antagonist,noncancer,53
acetophenazine,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,1,Launched,dopamine receptor antagonist,noncancer,53
2-iminobiotin,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12,0,Phase 2,nitric oxide synthase inhibitor,noncancer,72
valnemulin,CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
rociletinib,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,1,Phase 3,EGFR inhibitor,targeted cancer,10
propofol,CC(C)c1cccc(C(C)C)c1O,0,Launched,benzodiazepine receptor agonist,noncancer,44
famotidine,NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1,1,Launched,histamine receptor antagonist,noncancer,63
CCT018159,CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O,0,Preclinical,HSP inhibitor,targeted cancer,16
salicylic-acid,OC(=O)c1ccccc1O,0,Launched,cyclooxygenase inhibitor,noncancer,49
R547,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,1,Phase 1,CDK inhibitor,Unknown,5
felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC,0,Launched,calcium channel blocker,noncancer,45
clioquinol,Oc1c(I)cc(Cl)c2cccnc12,0,Withdrawn,chelating agent,noncancer,47
EMD-66684,CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Preclinical,angiotensin receptor antagonist,noncancer,36
SCH-28080,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,0,Phase 1,ATPase inhibitor,noncancer,2
tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer,28
PSB-11,CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1,0,Preclinical,adenosine receptor antagonist,noncancer,31
neostigmine,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer,29
GSK256066,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,1,Phase 2,phosphodiesterase inhibitor,noncancer,76
ML347,COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,0,Preclinical,ALK tyrosine kinase receptor inhibitor,targeted cancer,1
pifithrin-mu,NS(=O)(=O)C#Cc1ccccc1,0,Preclinical,HSP inhibitor,targeted cancer,16
chloroxine,Oc1c(Cl)cc(Cl)c2cccnc12,1,Launched,opioid receptor antagonist,noncancer,74
ODM-201,C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O,0,Phase 3,androgen receptor antagonist,Unknown,34
SB-431542,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1,1,Preclinical,TGF beta receptor inhibitor,targeted cancer,25
diclazuril,Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O,1,Launched,antiprotozoal agent,noncancer,38
nobiletin,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,1,Preclinical,MEK inhibitor,targeted cancer,18
cibenzoline,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,1,Launched,sodium channel blocker,noncancer,87
talinolol,CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1,0,Launched,adrenergic receptor antagonist,noncancer,33
olopatadine,CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12,0,Launched,histamine receptor antagonist,noncancer,63
GW-788388,O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1,1,Preclinical,ALK tyrosine kinase receptor inhibitor,noncancer,1
suramin,Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O,0,Launched,DNA synthesis inhibitor,noncancer,9
ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1,1,Launched,CDK inhibitor,targeted cancer,5
nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C,0,Launched,calcium channel blocker,noncancer,45
TAK-733,Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O,1,Phase 1,MEK inhibitor,targeted cancer,18
sevoflurane,FCOC(C(F)(F)F)C(F)(F)F,1,Launched,membrane integrity inhibitor,noncancer,68
zuclopenthixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1,0,Launched,dopamine receptor antagonist,noncancer,53
amyleine,CCC(C)(CN(C)C)OC(=O)c1ccccc1,0,Preclinical,local anesthetic,noncancer,66
BW-723C86,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,0,Preclinical,serotonin receptor agonist,noncancer,85
apraclonidine,Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1,0,Launched,adrenergic receptor agonist,noncancer,32
buphenine,CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer,32
PD-128907,CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21,0,Preclinical,dopamine receptor agonist,noncancer,52
tiapride,CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O,0,Launched,dopamine receptor antagonist,noncancer,53
metyrapone,CC(C)(C(=O)c1cccnc1)c1cccnc1,1,Launched,cytochrome P450 inhibitor,noncancer,50
MEK1-2-inhibitor,N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F,1,Preclinical,MEK inhibitor,noncancer,18
anpirtoline,Clc1cccc(SC2CCNCC2)n1,0,Phase 1,serotonin receptor agonist,noncancer,85
fiacitabine,Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,Phase 2,DNA synthesis inhibitor,noncancer,9
amisulpride,CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC,1,Launched,dopamine receptor antagonist,noncancer,53
alcaftadine,CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12,0,Launched,histamine receptor antagonist,noncancer,63
dizocilpine-(-),C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21,0,Phase 1,glutamate receptor antagonist,noncancer,60
IPI-145,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,Phase 3,PI3K inhibitor,targeted cancer,21
acepromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O,0,Launched,dopamine receptor antagonist,noncancer,53
hydroxyprogesterone-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,0,Launched,progesterone receptor agonist,noncancer,79
FK-888,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,1,Phase 2,tachykinin antagonist,noncancer,89
sulfamethoxypyridazine,COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1,0,Withdrawn,bacterial antifolate,noncancer,42
M-344,CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO,1,Preclinical,HDAC inhibitor,targeted cancer,14
tropicamide,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
chrysophanic-acid,Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,0,Preclinical,EGFR inhibitor,targeted cancer,10
trioxsalen,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,0,Launched,DNA synthesis inhibitor,noncancer,9
BIX-02189,CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1,0,Preclinical,MEK inhibitor,targeted cancer,18
roflumilast,FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl,0,Launched,phosphodiesterase inhibitor,noncancer,76
CZC24832,CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1,0,Preclinical,PI3K inhibitor,noncancer,21
mecamylamine,CNC1(C)C2CCC(C2)C1(C)C,0,Launched,acetylcholine receptor antagonist,noncancer,28
CB-10-277,CN(C)\N=N\c1ccc(cc1)C(O)=O,1,Phase 1,DNA synthesis inhibitor,chemo,9
FR-122047,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,1,Preclinical,cyclooxygenase inhibitor,noncancer,49
blebbistatin-(+/-),Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1,0,Preclinical,ATPase inhibitor,noncancer,2
chlorpyrifos,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,1,Launched,acetylcholinesterase inhibitor,noncancer,29
k-strophanthidin,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,1,Phase 2,ATPase inhibitor,targeted cancer,2
SB-222200,CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1,0,Preclinical,tachykinin antagonist,Unknown,89
moxaverine,CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1,0,Launched,phosphodiesterase inhibitor,noncancer,76
etoposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo,90
fosfosal,OC(=O)c1ccccc1OP(O)(O)=O,0,Launched,phosphodiesterase inhibitor,noncancer,76
diazepam,CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1,0,Launched,benzodiazepine receptor agonist,noncancer,44
teniposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo,90
ivermectin,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,1,Launched,benzodiazepine receptor agonist,noncancer,44
NECA,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,0,Launched,adenosine receptor agonist,noncancer,30
fenticonazole,Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
PIK-294,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O,0,Preclinical,PI3K inhibitor,targeted cancer,21
dipivefrine,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,0,Launched,adrenergic receptor agonist,noncancer,32
MLN-8054,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,1,Phase 1,Aurora kinase inhibitor,targeted cancer,3
busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,1,Launched,DNA inhibitor,chemo,7
SB-228357,COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F,1,Preclinical,serotonin receptor antagonist,noncancer,86
ACDPP,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,1,Preclinical,glutamate receptor antagonist,noncancer,60
decoquinate,CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC,0,Launched,antiprotozoal agent,noncancer,38
enzalutamide,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,1,Launched,androgen receptor antagonist,targeted cancer,34
ZSTK-474,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,1,Phase 1/Phase 2,PI3K inhibitor,targeted cancer,21
4-methylhistamine,Cc1nc[nH]c1CCN,1,Preclinical,histamine receptor agonist,noncancer,62
AZD4282,NCC(O)=O,0,Phase 1,glutamate receptor antagonist,noncancer,60
BNTX,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1,1,Preclinical,opioid receptor antagonist,noncancer,74
xibenolol,Cc1cccc(OCC(O)CNC(C)(C)C)c1C,0,Phase 3,adrenergic receptor antagonist,noncancer,33
griseofulvin,COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12,0,Launched,tubulin polymerization inhibitor,noncancer,91
mirabegron,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,0,Launched,adrenergic receptor agonist,noncancer,32
MTPG,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,1,Preclinical,glutamate receptor antagonist,noncancer,60
fentiazac,OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
piribedil,C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1,0,Launched,dopamine receptor agonist,noncancer,52
tolamolol,Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O,0,Phase 3,adrenergic receptor antagonist,noncancer,33
prucalopride,COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12,0,Launched,serotonin receptor agonist,noncancer,85
PD-0325901,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,1,Phase 2,MEK inhibitor,targeted cancer,18
YM-976,CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1,1,Phase 1,phosphodiesterase inhibitor,noncancer,76
benzonatate,CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,0,Launched,local anesthetic,noncancer,66
3-amino-benzamide,NC(=O)c1cccc(N)c1,1,Phase 2,PARP inhibitor,targeted cancer,20
ganetespib,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,1,Phase 3,HSP inhibitor,targeted cancer,16
triamterene,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,1,Launched,sodium channel blocker,noncancer,87
PD-318088,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,1,Preclinical,MEK inhibitor,targeted cancer,18
lazabemide,NCCNC(=O)c1ccc(Cl)cn1,0,Phase 3,monoamine oxidase inhibitor,noncancer,69
difloxacin,CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
flubendazole,COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1,1,Launched,tubulin polymerization inhibitor,noncancer,91
CHIR-98014,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,1,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
L-670596,CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1,0,Preclinical,prostanoid receptor antagonist,noncancer,80
fluspirilene,Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1,0,Launched,dopamine receptor antagonist,noncancer,53
lomefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,1,Launched,bacterial DNA gyrase inhibitor,noncancer,41
pranlukast,O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1,0,Launched,leukotriene receptor antagonist,noncancer,65
florfenicol,CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl,1,Launched,protein synthesis inhibitor,noncancer,81
eliprodil,OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,0,Phase 3,glutamate receptor antagonist,noncancer,60
silodosin,C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F,0,Launched,adrenergic receptor antagonist,noncancer,33
diethylstilbestrol,CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1,0,Withdrawn,estrogen receptor agonist,targeted cancer,56
PD-98059,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,1,Preclinical,MEK inhibitor,targeted cancer,18
etoricoxib,Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
UNC0737,COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,noncancer,64
aurora-a-inhibitor-i,CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1,1,Preclinical,Aurora kinase inhibitor,targeted cancer,3
solithromycin,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC,0,Phase 3,protein synthesis inhibitor,noncancer,81
ruxolitinib,N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,1,Launched,JAK inhibitor,targeted cancer,17
bevantolol,COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,0,Launched,adrenergic receptor antagonist,noncancer,33
pelitinib,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,1,Phase 2,EGFR inhibitor,targeted cancer,10
UNC0642,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
benzydamine,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,1,Launched,prostanoid receptor antagonist,noncancer,80
thioridazine,CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1,0,Withdrawn,dopamine receptor antagonist,targeted cancer,53
anisomycin,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,1,Preclinical,DNA synthesis inhibitor,noncancer,9
cefmenoxime,CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
CGH2466,Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1,0,Preclinical,adenosine receptor antagonist,noncancer,31
palovarotene,CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12,0,Phase 2,retinoid receptor agonist,noncancer,83
belinostat,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,1,Launched,HDAC inhibitor,targeted cancer,14
sulconazole,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer,88
PF-04447943,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2n(ncc2c(=O)[nH]1)C1CCOCC1,0,Phase 2,phosphodiesterase inhibitor,noncancer,76
pralidoxime-chloride,C[n+]1ccccc1C[N+][O-],0,Launched,acetylcholinesterase inhibitor,noncancer,29
mofezolac,COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
roxithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
fluorometholone,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,1,Launched,glucocorticoid receptor agonist,noncancer,58
WYE-125132,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,1,Preclinical,mTOR inhibitor,targeted cancer,67
EO-1428,Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,0,Preclinical,p38 MAPK inhibitor,noncancer,75
paracetamol,CC(=O)Nc1ccc(O)cc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
DMAB-anabaseine,CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1,0,Preclinical,adrenergic receptor agonist,noncancer,32
tropisetron,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12,1,Launched,serotonin receptor antagonist,noncancer,86
SB-242235,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,1,Phase 1,p38 MAPK inhibitor,noncancer,75
mizolastine,CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nccc(=O)[nH]1,0,Launched,histamine receptor antagonist,noncancer,63
trihexyphenidyl,OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
zibotentan,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1,0,Phase 3,endothelin receptor antagonist,targeted cancer,55
buparlisib,Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,1,Phase 3,PI3K inhibitor,targeted cancer,21
RS-16566,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,1,Preclinical,serotonin receptor antagonist,noncancer,86
suloctidil,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,0,Withdrawn,adrenergic receptor antagonist,noncancer,33
BD-1047,CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,0,Preclinical,adrenergic receptor antagonist,noncancer,33
AJ76-(+),CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,0,Preclinical,dopamine receptor antagonist,noncancer,53
piracetam,NC(=O)CN1CCCC1=O,0,Launched,acetylcholine receptor agonist,noncancer,27
azimilide,CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1,0,Phase 3,potassium channel blocker,Unknown,78
fleroxacin,CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O,1,Launched,topoisomerase inhibitor,noncancer,90
tarafenacin,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2,0,Phase 2,acetylcholine receptor antagonist,noncancer,28
VX-745,Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1,0,Phase 2,p38 MAPK inhibitor,targeted cancer,75
sulfachlorpyridazine,Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1,0,Launched,bacterial antifolate,noncancer,42
eltanolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Phase 3,membrane integrity inhibitor,noncancer,68
pozanicline,Cc1ncccc1OC[C@@H]1CCCN1,0,Phase 2,acetylcholine receptor antagonist,noncancer,28
hexamethonium,C[N+](C)(C)CCCCCC[N+](C)(C)C,0,Preclinical,cholinergic receptor antagonist,noncancer,48
nonoxynol-9,CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1,1,Launched,membrane integrity inhibitor,noncancer,68
PD-153035,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,1,Phase 1,EGFR inhibitor,targeted cancer,10
SAR407899,O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,0,Phase 2,rho associated kinase inhibitor,noncancer,84
NVP-BSK805,Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1,0,Preclinical,JAK inhibitor,targeted cancer,17
dasabuvir,COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1,0,Launched,HCV inhibitor,noncancer,13
fenofibric-acid,CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O,0,Launched,cytochrome P450 inhibitor,noncancer,50
medrysone,C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12,0,Launched,glucocorticoid receptor agonist,noncancer,58
PPT,CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1,1,Preclinical,estrogen receptor agonist,noncancer,56
dobutamine,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,0,Launched,adrenergic receptor agonist,noncancer,32
fosphenytoin,OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1,0,Launched,sodium channel blocker,noncancer,87
PG-9,CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,0,Preclinical,acetylcholine receptor agonist,noncancer,27
chloramphenicol-palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,1,Launched,protein synthesis inhibitor,noncancer,81
tiotropium,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1,0,Launched,acetylcholine receptor antagonist,Unknown,28
cyclopentolate,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,0,Launched,acetylcholine receptor antagonist,noncancer,28
AMPA-(RS),Cc1onc(O)c1CC(N)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
picrotoxinin,CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C,0,Preclinical,GABA receptor antagonist,noncancer,11
niguldipine-(S)-(+),COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1,0,Preclinical,adrenergic receptor antagonist,noncancer,33
flibanserin,FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1,0,Launched,serotonin receptor agonist,noncancer,85
oxaprozin,OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,Unknown,49
doxofylline,Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer,31
cortodoxone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,0,Phase 3,androgen receptor antagonist,noncancer,34
WB-4101,COc1cccc(OC)c1OCCNCC1COc2ccccc2O1,0,Preclinical,adrenergic receptor antagonist,noncancer,33
trimethoquinol,COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC,0,Launched,adrenergic receptor antagonist,noncancer,33
spiradoline,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,1,Phase 2,opioid receptor agonist,noncancer,73
etofylline,Cn1c2ncn(CCO)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer,31
darifenacin,NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer,28
enilconazole,Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer,88
TGX-221,CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1,0,Preclinical,PI3K inhibitor,targeted cancer,21
saclofen,NCC(CS(O)(=O)=O)c1ccc(Cl)cc1,0,Preclinical,GABA receptor antagonist,noncancer,11
fenobam,CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1,0,Phase 2,glutamate receptor antagonist,noncancer,60
AC-55649,CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O,0,Preclinical,retinoid receptor agonist,targeted cancer,83
dimpylate,CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer,29
selegiline,CC(Cc1ccccc1)N(C)CC#C,0,Launched,monoamine oxidase inhibitor,noncancer,69
RKI-1447,Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1,1,Preclinical,rho associated kinase inhibitor,targeted cancer,84
sitagliptin,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F,0,Launched,dipeptidyl peptidase inhibitor,noncancer,51
3-carboxy-4-hydroxyphenylglycine-(R),N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
AZD8055,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,1,Phase 1,mTOR inhibitor,Unknown,67
tirapazamine,Nc1n[n+]([O-])c2ccccc2[n+]1[O-],1,Phase 3,DNA inhibitor,chemo,7
VX-702,NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F,1,Phase 2,p38 MAPK inhibitor,noncancer,75
prinaberel,Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1,0,Phase 2,estrogen receptor agonist,noncancer,56
SB-742457,O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1,0,Phase 3,serotonin receptor antagonist,noncancer,86
dextroamphetamine,C[C@H](N)Cc1ccccc1,0,Launched,monoamine oxidase inhibitor,noncancer,69
uridine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O,1,Phase 2,dopamine receptor agonist,noncancer,52
"chromanol-293B-(-)-[3R,4S]",CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Preclinical,potassium channel blocker,noncancer,78
dianhydrogalactitol,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,1,Phase 1,DNA alkylating agent,chemo,6
estropipate,C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O,0,Launched,estrogen receptor agonist,noncancer,56
fosamprenavir,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,0,Launched,HIV protease inhibitor,noncancer,15
maxacalcitol,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],1,Launched,vitamin D receptor agonist,noncancer,92
CP-339818,CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12,0,Preclinical,potassium channel blocker,noncancer,78
deracoxib,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,0,Launched,cyclooxygenase inhibitor,noncancer,49
pentetic-acid,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,0,Phase 2,chelating agent,noncancer,47
R-96544,COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,0,Preclinical,serotonin receptor antagonist,noncancer,86
piboserod,CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1,0,Phase 2,serotonin receptor antagonist,noncancer,86
AS-703026,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,1,Phase 2,MEK inhibitor,targeted cancer,18
UNC0638,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
aptiganel,CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12,0,Phase 3,glutamate receptor antagonist,Unknown,60
omeprazole,COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C,1,Launched,ATPase inhibitor,noncancer,2
methiopril,CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O,0,Phase 2,angiotensin converting enzyme inhibitor,noncancer,35
doxercalciferol,CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer,92
cridanimod,OC(=O)Cn1c2ccccc2c(=O)c2ccccc12,0,Launched,progesterone receptor agonist,targeted cancer,79
benztropine-mesylate,CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
ASP3026,COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,0,Phase 1,ALK tyrosine kinase receptor inhibitor,targeted cancer,1
AR-42,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,1,Phase 1,HDAC inhibitor,targeted cancer,14
floxuridine,OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O,1,Launched,DNA synthesis inhibitor,chemo,9
dirithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
netupitant,CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1,0,Launched,tachykinin antagonist,noncancer,89
zotarolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1,0,Launched,mTOR inhibitor,noncancer,67
GSK163090,Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1,0,Phase 2,serotonin receptor antagonist,noncancer,86
terutroban,Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1,0,Phase 3,prostanoid receptor antagonist,noncancer,80
etonogestrel,CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C,0,Launched,progesterone receptor agonist,noncancer,79
naloxegol,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45,0,Launched,opioid receptor antagonist,noncancer,74
clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
propranolol-(S),CC(C)NC[C@H](O)COc1cccc2ccccc12,0,Preclinical,adrenergic receptor antagonist,targeted cancer,33
oxethazaine,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1,0,Launched,local anesthetic,noncancer,66
bupivacaine,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer,87
nexturastat-a,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,1,Preclinical,HDAC inhibitor,targeted cancer,14
triptolide,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O,1,Phase 3,RNA polymerase inhibitor,Unknown,24
bentazepam,O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,1,Launched,benzodiazepine receptor agonist,noncancer,44
otenzepad,CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12,0,Phase 3,acetylcholine receptor antagonist,noncancer,28
laropiprant,CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12,0,Launched,prostanoid receptor antagonist,noncancer,80
oxyfedrine,COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer,32
D-Serine,N[C@H](CO)C(O)=O,1,Launched,glutamate receptor agonist,noncancer,59
CL316243,C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1,0,Phase 2,adrenergic receptor agonist,noncancer,32
U-54494A,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer,73
bexarotene,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,1,Launched,retinoid receptor agonist,targeted cancer,83
RG2833,Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N,1,Phase 1,HDAC inhibitor,noncancer,14
1-acetyl-4-methylpiperazine,CN1CCN(CC1)C(C)=O,0,Preclinical,acetylcholine receptor agonist,noncancer,27
fenoterol,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,0,Withdrawn,adrenergic receptor agonist,noncancer,32
ioversol,OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,noncancer,82
itacitinib,Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,0,Phase 2,JAK inhibitor,targeted cancer,17
diazooxonorleucine,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,1,Phase 2,glutamate receptor antagonist,noncancer,60
AT-7519,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,1,Phase 2,CDK inhibitor,Unknown,5
perphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,0,Launched,dopamine receptor antagonist,noncancer,53
netilmicin,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O,0,Launched,protein synthesis inhibitor,noncancer,81
rifabutin,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21,0,Launched,protein synthesis inhibitor,noncancer,81
carboxyamidotriazole,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,1,Phase 3,calcium channel blocker,targeted cancer,45
tyloxapol,C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1,1,Launched,NFkB pathway inhibitor,Unknown,19
mepenzolate,C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
umeclidinium,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,0,Launched,acetylcholine receptor antagonist,noncancer,28
carvedilol,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,Launched,adrenergic receptor antagonist,noncancer,33
troxerutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,0,Launched,antioxidant,noncancer,37
posaconazole,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O,1,Launched,sterol demethylase inhibitor,noncancer,88
clobetasol-propionate,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer,58
clindamycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,0,Launched,protein synthesis inhibitor,noncancer,81
lorediplon,CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1,0,Phase 2,GABA receptor modulator,noncancer,12
nifenalol,CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O,0,Launched,adrenergic receptor antagonist,noncancer,33
MDL-72832,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,0,Preclinical,serotonin receptor agonist,noncancer,85
butylscopolamine-bromide,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,1,Launched,cholinergic receptor antagonist,noncancer,48
chloropyramine,CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,1,Launched,histamine receptor antagonist,noncancer,63
IB-MECA,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12,0,Phase 3,adenosine receptor agonist,targeted cancer,30
TAK-285,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,1,Phase 1,EGFR inhibitor,targeted cancer,10
SDZ-WAG-994,CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12,1,Phase 2,adenosine receptor agonist,noncancer,30
WYE-354,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,1,Preclinical,mTOR inhibitor,targeted cancer,67
tolmetin,Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C,0,Launched,cyclooxygenase inhibitor,noncancer,49
valaciclovir,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O,0,Launched,DNA polymerase inhibitor,noncancer,8
felbinac,OC(=O)Cc1ccc(cc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
ornidazole,Cc1ncc(n1CC(O)CCl)[N+]([O-])=O,0,Launched,antiprotozoal agent,noncancer,38
nitrocaramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,1,Preclinical,cholinergic receptor antagonist,noncancer,48
iododexetimide,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,1,Phase 2,acetylcholine receptor antagonist,noncancer,28
triprolidine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1,0,Launched,histamine receptor antagonist,noncancer,63
etoposide-phosphate,COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo,90
2-CMDO,CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,dopamine receptor antagonist,noncancer,53
trichostatin-a,C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C,1,Preclinical,HDAC inhibitor,Unknown,14
drotaverine,CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC,0,Launched,phosphodiesterase inhibitor,noncancer,76
UNC1999,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer,64
metronidazole,Cc1ncc(n1CCO)[N+]([O-])=O,1,Launched,DNA inhibitor,noncancer,7
prednisone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer,58
methoxamine,COc1ccc(OC)c(c1)C(O)C(C)N,0,Launched,adrenergic receptor agonist,noncancer,32
JNJ-10191584,CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1,0,Preclinical,histamine receptor antagonist,noncancer,63
penicillin-v-potassium,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
biperiden,OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
novobiocin,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C,1,Launched,bacterial DNA gyrase inhibitor,noncancer,41
dimesna,OS(=O)(=O)CCSSCCS(O)(=O)=O,0,Phase 3,tubulin polymerization inhibitor,noncancer,91
indomethacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
midafotel,OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1,0,Phase 3,glutamate receptor antagonist,noncancer,60
trequinsin,COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC,1,Phase 1,phosphodiesterase inhibitor,noncancer,76
hexoprenaline,OC(CNCCCCCCNCC(O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1,0,Launched,adrenergic receptor agonist,noncancer,32
ampicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
alaproclate,CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1,0,Phase 2,serotonin receptor antagonist,noncancer,86
XE-991,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12,0,Preclinical,potassium channel blocker,noncancer,78
talazoparib,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,1,Phase 3,PARP inhibitor,targeted cancer,20
MM77,COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,0,Preclinical,serotonin receptor antagonist,Unknown,86
cephapirin,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
zamifenacin,C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1,0,Phase 3,acetylcholine receptor antagonist,noncancer,28
bambuterol,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,0,Launched,adrenergic receptor agonist,noncancer,32
prednisolone-hemisuccinate,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,1,Preclinical,glucocorticoid receptor agonist,noncancer,58
omarigliptin,CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F,0,Launched,dipeptidyl peptidase inhibitor,noncancer,51
ARC-239,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,0,Preclinical,adrenergic receptor antagonist,noncancer,33
bakuchiol,CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1,0,Phase 2,DNA polymerase inhibitor,noncancer,8
poziotinib,COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C,1,Phase 2,EGFR inhibitor,targeted cancer,10
cilostamide,CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1,1,Preclinical,phosphodiesterase inhibitor,targeted cancer,76
oxatomide,O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Launched,histamine receptor antagonist,noncancer,63
vincamine,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,1,Withdrawn,adrenergic receptor antagonist,noncancer,33
RS-23597-190,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,0,Preclinical,serotonin receptor antagonist,noncancer,86
BCI-540,Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C,0,Phase 2,glutamate receptor agonist,noncancer,59
phenacemide,NC(=O)NC(=O)Cc1ccccc1,0,Launched,sodium channel blocker,noncancer,87
isoetharine,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,1,Launched,adrenergic receptor agonist,noncancer,32
GR-127935,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1,0,Preclinical,serotonin receptor antagonist,noncancer,86
1-azakenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
chlorpromazine,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,0,Launched,dopamine receptor antagonist,noncancer,53
epirubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,1,Launched,topoisomerase inhibitor,Unknown,90
isofloxythepin,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,1,Phase 2,dopamine receptor antagonist,noncancer,53
meglitinide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,1,Phase 2,potassium channel blocker,noncancer,78
MD-920,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O,0,Phase 1,NFkB pathway inhibitor,targeted cancer,19
matrine,O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34,0,Phase 2,opioid receptor agonist,targeted cancer,73
bemesetron,CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1,0,Phase 3,serotonin receptor antagonist,noncancer,86
propoxycaine,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,1,Launched,local anesthetic,noncancer,66
arbidol,CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,0,Launched,cytochrome P450 inhibitor,noncancer,50
saccharin,O=C1NS(=O)(=O)c2ccccc12,0,Launched,DNA polymerase inhibitor,noncancer,8
daclatasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,1,Launched,HCV inhibitor,noncancer,13
flutrimazole,Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1,0,Launched,sterol demethylase inhibitor,noncancer,88
PJ-34,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,1,Preclinical,PARP inhibitor,targeted cancer,20
sarpogrelate,COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1,0,Launched,serotonin receptor antagonist,noncancer,86
CH5132799,CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1,1,Phase 1,PI3K inhibitor,targeted cancer,21
darusentan,COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1,0,Phase 3,endothelin receptor antagonist,noncancer,55
osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,1,Launched,EGFR inhibitor,targeted cancer,10
BMS-649,CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O,0,Preclinical,retinoid receptor agonist,noncancer,83
temocapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,1,Launched,angiotensin converting enzyme inhibitor,noncancer,35
RS-127445,CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12,0,Phase 1,serotonin receptor antagonist,noncancer,86
norethindrone-acetate,CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,1,Launched,progesterone receptor agonist,noncancer,79
daidzein,Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,0,Phase 2,estrogen receptor agonist,targeted cancer,56
IEM1754,NCCCCCNCC12CC3CC(CC(C3)C1)C2,1,Preclinical,glutamate receptor antagonist,noncancer,60
bilastine,CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1,0,Launched,histamine receptor antagonist,noncancer,63
erlotinib,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,1,Launched,EGFR inhibitor,targeted cancer,10
fudosteine,N[C@@H](CSCCCO)C(O)=O,1,Launched,mucolytic agent,noncancer,70
glutathione,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,0,Phase 3,antioxidant,noncancer,37
fosfomycin,C[C@@H]1O[C@@H]1P(O)(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
MK-8745,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,1,Preclinical,Aurora kinase inhibitor,targeted cancer,3
tromaril,OC(=O)c1ccccc1NCCc1ccccc1,0,Launched,prostanoid receptor antagonist,noncancer,80
MDL-73005EF,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,0,Phase 1,serotonin receptor antagonist,noncancer,86
indacaterol,CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,0,Launched,adrenergic receptor agonist,Unknown,32
BAY-11-7085,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,1,Preclinical,NFkB pathway inhibitor,targeted cancer,19
FPL-55712,CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O,0,Phase 1,leukotriene receptor antagonist,noncancer,65
ML133,COc1ccc(CNCc2cccc3ccccc23)cc1,1,Preclinical,potassium channel blocker,targeted cancer,78
ambroxol,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,0,Launched,sodium channel blocker,noncancer,87
papaverine,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,1,Launched,phosphodiesterase inhibitor,noncancer,76
AS-604850,FC1(F)Oc2ccc(cc2O1)\C=C1/SC(=O)NC1=O,0,Preclinical,PI3K inhibitor,targeted cancer,21
mirodenafil,CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1,0,Launched,phosphodiesterase inhibitor,noncancer,76
nor-Binaltorphimine-dihydrochloride,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O,0,Preclinical,opioid receptor antagonist,noncancer,74
U-50488-(-),CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer,73
naringin,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O,0,Preclinical,cytochrome P450 inhibitor,noncancer,50
procaterol,CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,0,Launched,adrenergic receptor agonist,noncancer,32
anguidine,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,1,Phase 2,protein synthesis inhibitor,Unknown,81
deferiprone,Cc1c(O)c(=O)ccn1C,0,Launched,chelating agent,noncancer,47
Y-26763,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Phase 1,potassium channel activator,noncancer,77
arecoline,COC(=O)C1=CCCN(C)C1,0,Phase 1,acetylcholine receptor agonist,noncancer,27
exatecan-mesylate,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45,1,Phase 3,topoisomerase inhibitor,Unknown,90
ethoxzolamide,CCOc1ccc2nc(sc2c1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer,46
calcitriol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer,92
ST-91,CCc1cccc(CC)c1N=C1NCCN1,0,Preclinical,adrenergic receptor agonist,noncancer,32
bruceantin,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,1,Phase 2,protein synthesis inhibitor,Unknown,81
diltiazem,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,0,Launched,calcium channel blocker,noncancer,45
xylometazoline,Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C,0,Launched,adrenergic receptor agonist,noncancer,32
floctafenine,OCC(O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer,49
CTEP,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,0,Preclinical,glutamate receptor antagonist,noncancer,60
amonafide,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,1,Phase 3,topoisomerase inhibitor,chemo,90
acemetacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
metaproterenol,CC(C)NCC(O)c1cc(O)cc(O)c1,0,Launched,adrenergic receptor agonist,noncancer,32
flumethasone,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer,58
glycopyrrolate,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
5-carboxamidotryptamine,NCCc1c[nH]c2ccc(cc12)C(N)=O,0,Preclinical,serotonin receptor agonist,noncancer,85
linopirdine,O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1,0,Phase 3,potassium channel blocker,noncancer,78
pirinixic-acid,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,0,Preclinical,PPAR receptor agonist,noncancer,22
SKLB1002,COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,0,Preclinical,VEGFR inhibitor,targeted cancer,26
dolasetron,O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12,0,Launched,serotonin receptor antagonist,noncancer,86
gemifloxacin,CO\N=C1/CN(CC1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
cinalukast,CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O,1,Phase 2,leukotriene receptor antagonist,noncancer,65
clindamycin-palmitate,CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
nebracetam,NCC1CN(Cc2ccccc2)C(=O)C1,0,Phase 3,acetylcholine receptor agonist,noncancer,27
parthenolide,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,1,Phase 1,NFkB pathway inhibitor,targeted cancer,19
yohimbine,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,0,Launched,adrenergic receptor antagonist,noncancer,33
hydrocortisone-butyrate,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO,0,Launched,glucocorticoid receptor agonist,Unknown,58
cefditoren-pivoxil,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1,1,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
latrepirdine,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1,1,Phase 3,glutamate receptor antagonist,noncancer,60
trifluoperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,0,Launched,dopamine receptor antagonist,noncancer,53
AZD5069,C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,0,Phase 2,CC chemokine receptor antagonist,targeted cancer,4
danofloxacin,CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
3-AQC,C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N,0,Preclinical,serotonin receptor agonist,noncancer,85
midodrine,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,1,Launched,adrenergic receptor agonist,noncancer,32
linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
KW-2478,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,1,Phase 1/Phase 2,HSP inhibitor,targeted cancer,16
dolastatin-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,1,Phase 2,tubulin polymerization inhibitor,targeted cancer,91
HA-966-(S)-(-),N[C@H]1CCN(O)C1=O,0,Preclinical,glutamate receptor antagonist,noncancer,60
clofibrate,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,1,Launched,PPAR receptor agonist,noncancer,22
metaraminol,C[C@H](N)[C@H](O)c1cccc(O)c1,1,Launched,adrenergic receptor agonist,noncancer,32
emetine,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12,1,Phase 2,protein synthesis inhibitor,Unknown,81
PD-168393,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,1,Preclinical,EGFR inhibitor,targeted cancer,10
imidacloprid,[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
talmapimod,C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C,1,Phase 2,p38 MAPK inhibitor,targeted cancer,75
minocycline,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C,1,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer,39
brefeldin-a,C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1,1,Preclinical,protein synthesis inhibitor,Unknown,81
cis-urocanic acid,OC(=O)\C=C/c1c[nH]cn1,0,Phase 2,serotonin receptor agonist,targeted cancer,85
cyclandelate,CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1,0,Launched,calcium channel blocker,noncancer,45
torin-2,Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1,1,Preclinical,mTOR inhibitor,Unknown,67
TC2559,CCOc1cncc(\C=C\CCNC)c1,0,Preclinical,acetylcholine receptor agonist,noncancer,27
retigabine,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,0,Launched,potassium channel activator,noncancer,77
danirixin,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1,0,Phase 2,CC chemokine receptor antagonist,noncancer,4
vecuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer,28
AZD6765,NC(Cc1ccccn1)c1ccccc1,0,Phase 2,glutamate receptor antagonist,noncancer,60
arcyriaflavin-a,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,1,Preclinical,CDK inhibitor,targeted cancer,5
theobromine,Cn1cnc2n(C)c(=O)[nH]c(=O)c12,0,Launched,phosphodiesterase inhibitor,noncancer,76
metoxibutropate,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,1,Launched,cyclooxygenase inhibitor,noncancer,49
metharbital,CCC1(CC)C(=O)NC(=O)N(C)C1=O,0,Launched,GABA receptor modulator,noncancer,12
asunaprevir,COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12,0,Phase 3,HCV inhibitor,noncancer,13
adenosine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,0,Launched,adenosine receptor agonist,noncancer,30
calcipotriol,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Launched,vitamin D receptor agonist,noncancer,92
LY411575,C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O,0,Preclinical,gamma secretase inhibitor,noncancer,57
hexylcaine,CC(CNC1CCCCC1)OC(=O)c1ccccc1,0,Launched,sodium channel blocker,noncancer,87
nilutamide,CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,1,Launched,androgen receptor antagonist,targeted cancer,34
gaboxadol,Oc1noc2CNCCc12,0,Phase 3,benzodiazepine receptor agonist,noncancer,44
lappaconite,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,1,Phase 2,sodium channel blocker,noncancer,87
adenosine-phosphate,Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,0,Launched,adenosine receptor agonist,targeted cancer,30
deptropine,CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12,0,Preclinical,histamine receptor antagonist,noncancer,63
sitafloxacin,N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
PHA-793887,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,1,Phase 1,CDK inhibitor,targeted cancer,5
bethanechol,CC(C[N+](C)(C)C)OC(N)=O,0,Launched,acetylcholine receptor agonist,noncancer,27
ABT-751,COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1,1,Phase 2,tubulin polymerization inhibitor,chemo,91
WAY-161503,Clc1cc2NC(=O)C3CNCCN3c2cc1Cl,0,Preclinical,serotonin receptor agonist,noncancer,85
kynurenic-acid,OC(=O)c1cc(O)c2ccccc2n1,1,Preclinical,glutamate receptor antagonist,noncancer,60
azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
sutezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1,0,Phase 2,protein synthesis inhibitor,noncancer,81
L-165041,CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O,0,Preclinical,PPAR receptor agonist,noncancer,22
efaroxan,CCC1(Cc2ccccc2O1)C1=NCCN1,0,Phase 2,adrenergic receptor antagonist,noncancer,33
"L-732,138",CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,0,Preclinical,tachykinin antagonist,noncancer,89
mebendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,1,Launched,tubulin polymerization inhibitor,noncancer,91
PLX-4720,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,1,Preclinical,RAF inhibitor,targeted cancer,23
eprinomectin,CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,1,Launched,benzodiazepine receptor agonist,noncancer,44
medroxyprogesterone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12,0,Launched,progesterone receptor agonist,Unknown,79
S-Sulfo-L-cysteine-sodium-salt,N[C@@H](CSS(O)(=O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
cirazoline,C(Oc1ccccc1C1CC1)C1=NCCN1,0,Preclinical,adrenergic receptor agonist,noncancer,32
CD-1530,OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2,0,Preclinical,retinoid receptor agonist,noncancer,83
ofloxacin,CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
TG-100713,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,1,Preclinical,PI3K inhibitor,targeted cancer,21
terodiline,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,0,Phase 3,cholinergic receptor antagonist,noncancer,48
olanzapine,CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",Unknown,54
piclamilast,COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl,0,Phase 2,phosphodiesterase inhibitor,noncancer,76
preladenant,COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1,0,Phase 3,adenosine receptor antagonist,targeted cancer,31
2-PMDQ,O=C1Nc2ccccc2C2=NC(CN3CCN(CC3)c3ccccc3)CN12,0,Preclinical,adrenergic receptor antagonist,noncancer,33
epinastine,NC1=NCC2N1c1ccccc1Cc1ccccc21,1,Launched,histamine receptor antagonist,noncancer,63
valsartan,CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O,0,Launched,angiotensin receptor antagonist,noncancer,36
fluocinolone-acetonide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer,58
sulfafurazole,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,0,Launched,bacterial antifolate,noncancer,42
stepronin,CC(SC(=O)c1cccs1)C(=O)NCC(O)=O,0,Launched,mucolytic agent,noncancer,70
rimexolone,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer,58
5'-Chloro-5'-deoxy-ENBA-(+/-),O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12,0,Preclinical,adenosine receptor agonist,Unknown,30
aminosalicylate,Nc1ccc(C(O)=O)c(O)c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
cefepime,CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
oritavancin,CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
levofloxacin,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer,41
cephalothin,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
arofylline,CCCn1c(=O)n(-c2ccc(Cl)cc2)c2[nH]cnc2c1=O,0,Phase 3,phosphodiesterase inhibitor,noncancer,76
naratriptan,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,0,Launched,serotonin receptor agonist,noncancer,85
clonidine,Clc1cccc(Cl)c1N=C1NCCN1,0,Launched,adrenergic receptor agonist,noncancer,32
cefetamet,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
olmesartan,CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O,0,Launched,angiotensin receptor antagonist,noncancer,36
Ro-106-9920,O=S(c1ccccc1)c1ccc2nnnn2n1,1,Preclinical,NFkB pathway inhibitor,noncancer,19
L-Cysteinesulfinic-acid,N[C@@H](CS(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer,59
haloperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,0,Launched,dopamine receptor antagonist,noncancer,53
primidone,CCC1(C(=O)NCNC1=O)c1ccccc1,0,Launched,GABA receptor antagonist,noncancer,11
ropinirole,CCCN(CCC)CCc1cccc2NC(=O)Cc12,0,Launched,dopamine receptor agonist,noncancer,52
naloxone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,1,Launched,opioid receptor antagonist,noncancer,74
mephenesin,Cc1ccccc1OCC(O)CO,0,Launched,muscle relaxant,noncancer,71
bepotastine,OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,Unknown,63
cloranolol,CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl,0,Launched,adrenergic receptor antagonist,noncancer,33
etanidazole,OCCNC(=O)Cn1ccnc1[N+]([O-])=O,0,Phase 3,bacterial cell wall synthesis inhibitor,targeted cancer,43
AMD11070,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12,0,Phase 1/Phase 2,CC chemokine receptor antagonist,targeted cancer,4
volinanserin,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,0,Phase 3,serotonin receptor antagonist,noncancer,86
quinpirol-(-),CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12,0,Phase 2,dopamine receptor agonist,noncancer,52
flecainide,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1,0,Launched,sodium channel blocker,noncancer,87
terfenadine,CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,1,Withdrawn,histamine receptor antagonist,noncancer,63
SR-33805,COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC,1,Phase 1,calcium channel blocker,noncancer,45
enciprazine,COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1,0,Phase 3,GABA receptor modulator,noncancer,12
candesartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,1,Launched,angiotensin receptor antagonist,noncancer,36
cefonicid,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
sulbutiamine,CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O,0,Launched,acetylcholine receptor antagonist,noncancer,28
hydrocortisone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer,58
ceritinib,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0,Launched,ALK tyrosine kinase receptor inhibitor,Unknown,1
labetalol,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O,0,Launched,adrenergic receptor antagonist,noncancer,33
SB-216763,Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12,0,Preclinical,glycogen synthase kinase inhibitor,noncancer,61
pipemidic-acid,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1,0,Launched,topoisomerase inhibitor,noncancer,90
levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,0,Launched,calcium channel blocker,noncancer,45
dalfampridine,Nc1ccncc1,0,Launched,potassium channel blocker,noncancer,78
dimethisoquin,CCCCc1cc2ccccc2c(OCCN(C)C)n1,1,Launched,local anesthetic,noncancer,66
NGB-2904,Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl,0,Preclinical,dopamine receptor antagonist,noncancer,53
ondansetron,Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C,0,Launched,serotonin receptor antagonist,noncancer,86
altanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,0,Phase 2,serotonin receptor antagonist,noncancer,86
cyproterone-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,1,Launched,androgen receptor antagonist,targeted cancer,34
EIT-hydrobromide,CCSC(N)=N,0,Preclinical,nitric oxide synthase inhibitor,noncancer,72
lodoxamide,OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N,0,Launched,histamine receptor antagonist,noncancer,63
MK-5108,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,1,Phase 1,Aurora kinase inhibitor,targeted cancer,3
pinitol,COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O,0,Phase 2,gamma secretase inhibitor,noncancer,57
CEP-32496,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,1,Phase 1/Phase 2,RAF inhibitor,targeted cancer,23
sulmazole,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,1,Phase 1,adenosine receptor antagonist,noncancer,31
enprofylline,CCCn1c2nc[nH]c2c(=O)[nH]c1=O,0,Phase 3,phosphodiesterase inhibitor,noncancer,76
fidaxomicin,CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O,0,Launched,RNA polymerase inhibitor,noncancer,24
desonide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer,58
narlaprevir,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,1,Phase 2/Phase 3,HCV inhibitor,noncancer,13
spiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1,0,Launched,dopamine receptor antagonist,noncancer,53
alimemazine,CC(CN(C)C)CN1c2ccccc2Sc2ccccc12,0,Launched,histamine receptor agonist,noncancer,62
polidocanol,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,0,Launched,local anesthetic,noncancer,66
zolmitriptan,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,1,Launched,serotonin receptor agonist,noncancer,85
1-EBIO,CCn1c2ccccc2[nH]c1=O,0,Preclinical,potassium channel activator,noncancer,77
rivanicline,CNCC\C=C\c1cccnc1,0,Phase 2,acetylcholine receptor agonist,noncancer,27
fasudil,O=S(=O)(N1CCCNCC1)c1cccc2cnccc12,0,Launched,rho associated kinase inhibitor,noncancer,84
nifurtimox,CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O,0,Launched,DNA inhibitor,noncancer,7
piromidic-acid,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1,0,Phase 2,bacterial DNA gyrase inhibitor,noncancer,41
rubitecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,1,Phase 3,topoisomerase inhibitor,chemo,90
10-DEBC,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,AKT inhibitor,targeted cancer,0
delamanid,C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
benznidazole,[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1,0,Launched,DNA synthesis inhibitor,noncancer,9
rasagiline,C#CCN[C@@H]1CCc2ccccc12,0,Launched,monoamine oxidase inhibitor,noncancer,69
benzamil,NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N,0,Phase 2,sodium channel blocker,noncancer,87
bromhexine,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1,0,Launched,mucolytic agent,noncancer,70
2-aminobenzenesulfonamide,Nc1ccccc1S(N)(=O)=O,0,Preclinical,carbonic anhydrase inhibitor,Unknown,46
SDZ-NKT-343,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O,0,Phase 1,tachykinin antagonist,noncancer,89
flavoxate,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
MPEP,Cc1cccc(n1)C#Cc1ccccc1,0,Preclinical,glutamate receptor antagonist,noncancer,60
halobetasol-propionate,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer,58
adapalene,COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O,1,Launched,retinoid receptor agonist,noncancer,83
famprofazone,CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C,0,Preclinical,cyclooxygenase inhibitor,noncancer,49
tizanidine,Clc1ccc2nsnc2c1NC1=NCCN1,0,Launched,adrenergic receptor agonist,noncancer,32
ginkgolide-a,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,1,Preclinical,GABA receptor antagonist,noncancer,11
bufexamac,CCCCOc1ccc(CC(=O)NO)cc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer,49
tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,1,Phase 3,VEGFR inhibitor,targeted cancer,26
RS-504393,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,1,Preclinical,CC chemokine receptor antagonist,noncancer,4
bepridil,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,0,Launched,calcium channel blocker,noncancer,45
clonixin-lysinate,NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O,0,Launched,cyclooxygenase inhibitor,Unknown,49
ipratropium,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
deforolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O,1,Phase 3,mTOR inhibitor,targeted cancer,67
hexylresorcinol,CCCCCCc1ccc(O)cc1O,1,Launched,local anesthetic,Unknown,66
varenicline,C1C2CNCC1c1cc3nccnc3cc21,0,Launched,acetylcholine receptor agonist,noncancer,27
seocalcitol,CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Phase 3,vitamin D receptor agonist,targeted cancer,92
tilmicosin,CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer,40
donepezil,COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC,0,Launched,acetylcholinesterase inhibitor,noncancer,29
DBeQ,C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1,0,Preclinical,ATPase inhibitor,targeted cancer,2
LY456236,COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,1,Preclinical,glutamate receptor antagonist,noncancer,60
paclitaxel,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1,1,Launched,tubulin polymerization inhibitor,chemo,91
thiethylperazine,CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,0,Launched,dopamine receptor antagonist,noncancer,53
aminopentamide,CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,0,Launched,acetylcholine receptor antagonist,noncancer,28
dapiprazole,Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1,0,Launched,adrenergic receptor antagonist,noncancer,33
gadoterate-meglumine,OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1,0,Launched,radiopaque medium,noncancer,82
decamethonium,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,0,Launched,acetylcholine receptor agonist,noncancer,27
equilin,CC12CCC3C(=CCc4cc(O)ccc34)C1CCC2=O,0,Preclinical,estrogen receptor agonist,noncancer,56
CYC116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,1,Phase 1,Aurora kinase inhibitor,targeted cancer,3
valdecoxib,Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer,49
"L-798,106",COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1,1,Preclinical,prostanoid receptor antagonist,noncancer,80
desoximetasone,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer,58
aceclofenac,OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,0,Launched,prostanoid receptor antagonist,noncancer,80
TAK-632,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,1,Preclinical,RAF inhibitor,targeted cancer,23
salirasib,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O,0,Phase 2,mTOR inhibitor,targeted cancer,67
DMH1,CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,1,Preclinical,ALK tyrosine kinase receptor inhibitor,targeted cancer,1
cefotetan,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
telmesteine,CCOC(=O)N1CSCC1C(O)=O,0,Launched,mucolytic agent,noncancer,70
irsogladine,Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl,0,Launched,phosphodiesterase inhibitor,noncancer,76
oxolinic-acid,CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12,0,Preclinical,bacterial DNA gyrase inhibitor,noncancer,41
tulobuterol,CC(C)(C)NCC(O)c1ccccc1Cl,0,Launched,adrenergic receptor agonist,noncancer,32
niflumic-acid,OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer,49
EVP-6124,Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2,0,Phase 3,acetylcholine receptor agonist,noncancer,27
teroxirone,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,1,Phase 1,DNA inhibitor,chemo,7
L-Theanine,CCNC(=O)CCC(N)C(O)=O,0,Launched,glutamate receptor antagonist,noncancer,60
diarylpropionitrile,Oc1ccc(CC(C#N)c2ccc(O)cc2)cc1,0,Preclinical,estrogen receptor agonist,targeted cancer,56
cortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,0,Launched,glucocorticoid receptor agonist,noncancer,58
piperonyl-butoxide,CCCCOCCOCCOCc1cc2OCOc2cc1CCC,0,Launched,cytochrome P450 inhibitor,noncancer,50
methylprednisolone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,Launched,glucocorticoid receptor agonist,noncancer,58
beclomethasone-dipropionate,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer,58
BP-897,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,0,Phase 2,dopamine receptor agonist,noncancer,52
chromanol-(+/-),CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Preclinical,potassium channel blocker,Unknown,78
pafuramidine,CONC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(=N)NOC,0,Phase 3,DNA synthesis inhibitor,targeted cancer,9
S26948,COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC,1,Preclinical,PPAR receptor agonist,noncancer,22
gabapentin,NCC1(CC(O)=O)CCCCC1,0,Launched,calcium channel blocker,noncancer,45
nesbuvir,CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1,0,Phase 2,RNA polymerase inhibitor,noncancer,24
ritanserin,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1,0,Phase 3,serotonin receptor antagonist,noncancer,86
toltrazuril,Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O,0,Launched,antiprotozoal agent,noncancer,38
lofemizole,Cc1nc[nH]c1-c1ccc(Cl)cc1,0,Phase 3,cyclooxygenase inhibitor,noncancer,49
piricapiron,CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O,0,Phase 2,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer,54
gabazine,COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1,0,Preclinical,GABA receptor antagonist,noncancer,11
etizolam,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,0,Launched,benzodiazepine receptor agonist,noncancer,44
carebastine,CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,0,Phase 1,histamine receptor antagonist,Unknown,63
ciproxifan,O=C(C1CC1)c1ccc(OCCCc2c[nH]cn2)cc1,0,Preclinical,histamine receptor antagonist,Unknown,63
flunarizine,Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,0,Launched,calcium channel blocker,noncancer,45
formoterol,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,0,Launched,adrenergic receptor agonist,noncancer,32
alclofenac,OC(=O)Cc1ccc(OCC=C)c(Cl)c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
GSK429286A,CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F,1,Preclinical,rho associated kinase inhibitor,noncancer,84
AM-580,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O,1,Preclinical,retinoid receptor agonist,targeted cancer,83
EMD-386088,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1,0,Preclinical,serotonin receptor agonist,noncancer,85
trelagliptin,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O,0,Launched,dipeptidyl peptidase inhibitor,noncancer,51
AM-92016,CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1,0,Preclinical,potassium channel blocker,noncancer,78
HA-966-(R)-(+),N[C@@H]1CCN(O)C1=O,0,Preclinical,glutamate receptor agonist,noncancer,59
mebeverine,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,0,Launched,acetylcholine receptor antagonist,noncancer,28
terconazole,CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer,88
omeprazole-sulfide,COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1,0,Phase 1,ATPase inhibitor,noncancer,2
ritodrine,C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer,32
tomelukast,CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O,0,Phase 3,leukotriene receptor antagonist,noncancer,65
mosapride,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,0,Launched,serotonin receptor agonist,noncancer,85
ioxilan,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,noncancer,82
alclometasone-dipropionate,CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,0,Launched,glucocorticoid receptor agonist,noncancer,58
CGP-12177,CC(C)(C)NCC(O)COc1cccc2[nH]c(O)nc12,0,Phase 1,adrenergic receptor agonist,noncancer,32
eprazinone,CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1,0,Launched,mucolytic agent,noncancer,70
azilsartan-medoxomil,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,0,Launched,angiotensin receptor antagonist,noncancer,36
eprosartan,CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O,1,Launched,angiotensin receptor antagonist,noncancer,36
olsalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer,49
flucloxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
tazemetostat,CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1,1,Phase 2,histone lysine methyltransferase inhibitor,targeted cancer,64
letosteine,CCOC(=O)CSCCC1NC(CS1)C(O)=O,0,Launched,mucolytic agent,noncancer,70
enalaprilat,C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,Unknown,35
piperazine,C1CNCCN1,1,Launched,benzodiazepine receptor agonist,noncancer,44
memantine,CC12CC3CC(C)(C1)CC(N)(C3)C2,0,Launched,glutamate receptor antagonist,noncancer,60
avanafil,COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl,1,Launched,phosphodiesterase inhibitor,noncancer,76
AQ-RA741,CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,0,Preclinical,acetylcholine receptor antagonist,noncancer,28
nedocromil,CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O,0,Launched,histamine receptor antagonist,noncancer,63
4E1RCat,OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O,1,Preclinical,protein synthesis inhibitor,noncancer,81
doxylamine,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer,63
17-hydroxyprogesterone-caproate,CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,0,Launched,progesterone receptor agonist,targeted cancer,79
tranylcypromine,N[C@H]1C[C@@H]1c1ccccc1,0,Launched,monoamine oxidase inhibitor,noncancer,69
"5,7-dichlorokynurenic-acid",OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1,0,Preclinical,glutamate receptor antagonist,noncancer,60
talniflumate,FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1,0,Launched,cyclooxygenase inhibitor,noncancer,49
flurbiprofen-(+/-),CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer,49
anabasine,C1CCC(NC1)c1cccnc1,0,Preclinical,acetylcholine receptor agonist,Unknown,27
halcinonide,CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer,58
candesartan-cilextil,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,noncancer,36
ginsenoside-rd,CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,0,Phase 3,calcium channel blocker,noncancer,45
dabrafenib,CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F,1,Launched,RAF inhibitor,targeted cancer,23
piperine,O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1,1,Phase 1,monoamine oxidase inhibitor,targeted cancer,69
tyrphostin-AG-1478,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,1,Preclinical,EGFR inhibitor,targeted cancer,10
SB-206553,Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1,0,Preclinical,serotonin receptor antagonist,noncancer,86
2-chloro-N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12,0,Preclinical,adenosine receptor agonist,noncancer,30
losmapimod,Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1,0,Phase 3,p38 MAPK inhibitor,noncancer,75
butacaine,CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1,0,Launched,local anesthetic,Unknown,66
TMC647055,COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O,0,Phase 2,RNA polymerase inhibitor,noncancer,24
N-MPPP,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1,0,Preclinical,opioid receptor agonist,noncancer,73
proadifen,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,0,Preclinical,nitric oxide synthase inhibitor,noncancer,72
oxaliplatin,O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O,1,Launched,DNA inhibitor,chemo,7
vinorelbine,CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,1,Launched,tubulin polymerization inhibitor,chemo,91
cyanopindolol,CC(C)(C)NCC(O)COc1cccc2[nH]c(cc12)C#N,0,Phase 2,adrenergic receptor antagonist,noncancer,33
dihydroergotamine,CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,0,Launched,serotonin receptor agonist,noncancer,85
N-methylquipazine,CN1CCN(CC1)c1ccc2ccccc2n1,0,Preclinical,serotonin receptor agonist,noncancer,85
daptomycin,CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer,43
CO-101244,Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,0,Preclinical,glutamate receptor antagonist,noncancer,60
WZ8040,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,1,Preclinical,EGFR inhibitor,targeted cancer,10
